THE ROLE OF CD73 IN GLIOBLASTOMA PATHOGENESIS AND ANTI-GLIOBLASTOMA IMMUNE RESPONSE by Yan, Angela
  
 
 
THE ROLE OF CD73 IN GLIOBLASTOMA PATHOGENESIS AND ANTI-
GLIOBLASTOMA IMMUNE RESPONSE 
 
 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
in Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
by 
Angela Yan 
May 2019
  
 
© 2019 Angela Yan
  
 
THE ROLE OF CD73 IN GLIOBLASTOMA PATHOGENESIS AND ANTI-
GLIOBLASTOMA IMMUNE RESPONSE 
Angela Yan, Ph.D. 
Cornell University 2019 
 CD73 is a key enzyme in extracellular ATP metabolism; it converts AMP to 
extracellular adenosine. CD73 is involved in many cellular functions, including cell 
adhesion, cell proliferation, tumor invasion, and angiogenesis. Because of its enzymatic 
activity, CD73 is also a key immune regulator. CD73-generated extracellular adenosine 
signals through the A2A adenosine receptor (AR) on leukocytes to attenuate 
inflammation and restore immune homeostasis. Because of these properties, CD73 is 
used by tumor cells to promote their pathogenesis and attenuate the host anti-tumor 
immune response. In this dissertation, we investigated the role of CD73 in glioblastoma 
(GB) pathogenesis and anti-GB immune response. 
 We implanted mouse GB cells in wild type (WT) and CD73-/- mice. We found 
that GB-bearing CD73-/- mice had reduced tumor size and invasiveness and decreased 
tumor vessel density compared with GB-bearing WT mice. To investigate whether host 
CD73 promoted GB invasiveness, we generated the CD73-FLK mice from the CD73-/- 
mice by enforcing CD73 expression on endothelial cells. GB-bearing CD73-FLK mice 
had the most invasive tumors compared with GB-bearing WT and CD73-/- mice, 
suggesting that the limited host CD73 on endothelial cells increased GB invasiveness. 
We also found a 20-fold upregulation of the A2B AR in GB, which is rarely expressed 
in the central nervous system under physiological conditions and only upregulated 
during pathological conditions. Inhibition of A2B AR signaling decreased the 
permeability glycoprotein (P-gp) and the multidrug resistance-associated protein 1 
  
 
(MRP1) expression on mouse GB cells and made GB cells more susceptible to 
temozolomide-induced cell death. Additionally, we found that GB-bearing CD73-/- mice 
mounted a stronger inflammatory response to GB than GB-bearing WT mice. Compared 
with GB-bearing WT mice, GB-bearing CD73-/- mice had increased anti-inflammatory 
cytokine IL-10 and reduced pro-inflammatory cytokines TNF-α and IL-1β. Further, GB-
infiltrating regulatory T cells and M2 microglia/macrophages were reduced in GB-
bearing CD73-/- mice, whereas GB-infiltrating CD8+ T cells were increased. 
 Together, these findings suggest that CD73 is used by GB to promote its 
pathogenesis through increasing GB angiogenesis, invasion, and chemoresistance. Our 
data also suggest that GB evades the host immune response by using CD73 to attenuate 
inflammatory responses. Therefore, targeting the CD73-AR axis presents great 
potentials for future GB therapeutic interventions. 
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CHAPTER 1 
 
Introduction 
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Significance 
Glioblastoma multiforme (GB) is the most aggressive primary malignant brain 
tumor that affects humans. Current standard treatments for GB include surgical 
resection, chemotherapy with temozolomide (TMZ), and radiation therapy. GB is highly 
invasive and often infiltrates the surrounding non-neoplastic brain tissue. This makes 
complete surgical removal difficult and sometimes impossible. Incomplete GB 
resection leads to recurrence and reduced overall survival. Additionally, because the 
tumor is located in the central nervous system (CNS), surgical removal and 
chemotherapeutic drug delivery is extremely challenging. The blood-brain barrier 
(BBB) blocks chemotherapeutic drug delivery to the brain, and GB is resistant to 
chemotherapy (1). Therefore, GB patients have a very poor prognosis, with a median 
survival time of 18 months even with treatment. 
CD73 and extracellular adenosine have been implicated in many types of 
cancers (2) and are key regulators in attenuating the immune response during 
inflammatory conditions (3). This dissertation focuses on the mechanism by which 
CD73 and adenosine/adenosine receptor pathway contribute to GB pathogenesis by 
promoting its growth, invasiveness, and chemoresistance, or by modulating the host 
immune response to GB. 
Glioblastoma Multiforme 
Epidemiology and Etiology 
GB occurs mostly in elderly people with a median age at diagnosis of 64 (4). 
90% of GB develops de novo (primary GB), while less than 10% progresses from a 
lower grade astrocytoma (5), also known as secondary GB. Unlike primary GB, 
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secondary GB is prevalent in young patients (4). 68% of primary GB patients have a 
short clinical history (from first symptoms to histological diagnosis) of less than 3 
months, while secondary GB patients often have years of clinical history (5). The signs 
and symptoms of GB patients often differ based on the tumor size, growth rate, and 
location in the brain. GB symptoms generally arise from necrosis of the brain tissue, 
increased intracranial pressure, and/or its location in specific regions of the brain, which 
result in reduced or loss of brain functions (6, 7). Necrosis of the brain tissue often leads 
to cognitive impairments, loss of vision, hearing problems, and/or personality changes 
caused by cognitive impairments. Other GB symptoms include headaches, nausea, 
vomiting, memory loss, speech difficulties, and seizures. 
Although GB cells are highly heterogeneous, they mostly originate from 
astrocytes, neural stem cells, or oligodendrocyte precursor cells (4). The cause of GB is 
currently unclear. However, we know that only a small percentage of GB is associated 
with hereditary factors (8). It has also been shown that GB is associated with increased 
exposure to ionizing radiation (9), high dietary intake of sugar (10), and exposure to 
human cytomegalovirus infection (7). Studies involving the genetic mutations of GB 
have shown that GB from different patient samples possess many common genetic 
mutations. Between 47 and 69% of GB showed a loss of heterozygosity in chromosome 
10q (11, 12), and 34% of GB had EGFR amplification, p16INK4a deletion, or PTEN 
mutation (12). Chromosome 10q has many tumor suppressor genes, including PTEN, 
and allelic loss of 10q is often associated with tumorigenesis. 
Current Treatments and Challenges 
Current standard treatment for GB is a combination of surgical resection, 
radiation therapy, and chemotherapy. Due to the invasive nature of GB, surgical 
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resection is challenging, and it often does not remove all tumor tissue, which leads to 
recurrence. Currently, the only chemotherapeutic drug available for GB is 
temozolomide (TMZ). TMZ is a small lipophilic alkylating agent prodrug, which 
delivers a methyl group to O6-guanine and generates O6-methylguanine (13). O6-
methylguanine pairs with thymine during replication and results in a mismatch (14). 
This O6-methylguanine:thymine mismatch then leads to cell death. Unlike most 
chemotherapeutic drugs, TMZ is not completely blocked by the blood-brain barrier 
(BBB) because of its small size (194 Da) and lipophilic properties. However, some GB 
cells express O6-methylguanine-DNA methyltransferase (MGMT), which repairs DNA 
mismatch in GB, making them resistant to TMZ (15, 16). Further, GB expresses 
multidrug resistance transporters, such as the permeability glycoprotein (P-gp) and the 
multidrug resistance-associated protein 1 (MRP1) (17). These transporters can actively 
pump out chemotherapeutic drugs and make GB chemoresistant. Although GB is 
resistant to TMZ, studies have shown that epigenetic silencing of MGMT through 
methylation of the cysteine-phosphate-guanine (CpG) island on MGMT promoter is 
associated with increased TMZ efficacy (1, 18). This allows us to identify TMZ-
susceptible GB patients and perform treatments accordingly. 
Novel therapeutics, such as treatment with bevacizumab, an anti-vascular 
endothelial growth factor A (VEGF-A) antibody, was approved by the FDA in 2009 for 
GB. However, even though it was effective in other cancers, including lung cancer (19) 
and ovarian cancer (20, 21), bevacizumab only slightly prolonged progression-free 
survival and had no effect on the overall survival rate of GB patients (22). 
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CD73 and Extracellular Adenosine 
Ecto-5’-nucleotidase (CD73) 
Ecto-5’-nucleotidase, also known as CD73, is a glycosyl phosphatidylinositol 
(GPI)-anchored surface enzyme on eukaryotic cells. In naïve animals, CD73 is 
expressed in various tissues, including the colon, kidney, brain, lung, liver, heart, and 
muscle (23). The C-terminus of CD73 creates a noncovalent link between its two 
subunits to maintain a homodimer form (24). An α helix connects the N and C-terminal 
domains of CD73, allowing CD73 to alternate between an open and a closed 
conformation (24, 25) (Figure 1.1). This change in conformation allows CD73 to induce 
substrate binding and release during catalytic reactions (25–28). CD73 catalyzes the 
final step of adenosine triphosphate (ATP) hydrolysis and converts adenosine 
monophosphate (AMP) into adenosine and an inorganic phosphate. This catalytic 
activity of CD73 makes it the predominant regulator of extracellular adenosine 
production. Besides its enzymatic activity, CD73 also acts as a costimulatory molecule 
in T cell activation (29–32). Furthermore, extracellular adenosine generated by CD73 
is a potent immune regulator through adenosine receptor signaling. Because of its 
immunoregulatory properties, CD73 is a highly desirable target for modulating immune 
responses in cancers, autoimmune diseases, and infectious diseases. 
Extracellular Adenosine  
Adenosine is a purine nucleoside that regulates a wide array of host functions 
(33). During tissue damage, ATP is released into the extracellular space, then broken 
down into ADP and AMP by the surface enzyme ectonucleoside triphosphate 
diphosphohydrolase-1 (CD39) (Figure 1.2). AMP is further converted to adenosine by 
CD73 (Figure 1.2). Purine nucleosides are signaling molecules that sense and signal
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Figure 1.1 CD73 structure 
An α helix connects the N and C-terminal domains of CD73, allowing CD73 to alternate 
between an open and a closed conformation. Transitioning between the open and the 
closed (active) conformation induce substrate binding and release during catalytic 
reactions. 
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Figure 1.2 Schematic of ATP and adenosine metabolism. 
Extracellular adenosine is produced from ATP released in the extracellular environment 
upon cell damage and is converted to ADP and AMP by CD39. AMP is further 
converted to adenosine by CD73. Extracellular adenosine binds to its receptors to 
mediate its function. Extracellular adenosine is rapidly degraded to inosine by adenosine 
deaminase (ADA).
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danger, distress and/or tissue damage (34, 35). This is most evident in hypoxic and 
ischemic conditions in the heart, lungs, and central nervous system (CNS). Adenosine 
functions as a countermeasure, or safety signal, to counteract the ATP signal. It helps 
restrain harmful immune responses, recruits cells and molecules to the site of tissue 
damage, and induces various cellular factors that signal the termination and repair of 
injured tissue (35). Further, extracellular (CD73-generated) adenosine is a potent 
immune suppressor and has been shown to create an immunosuppressive tumor 
microenvironment (36). Adenosine mediates its effects via four G protein-coupled 
receptors, which are the A1, A2A, A2B and A3 adenosine receptors (ARs). ARs bind to 
adenosine with different affinities. The A1 AR and A2A AR have a high affinity for 
adenosine (70 nM and 150 nM respectively), while the A2B and A3 AR have a much 
lower affinity for adenosine (5100 nM and 6500 nM respectively) (37). Because of its 
wide-ranging effects, adenosine is used by many tumors to promote tumor malignancy 
through immune modulation, promotion of angiogenesis, and regulation of angiogenic 
and hypoxic genes, all of which are critical for tumor progression (38–41). 
The Blood-Brain Barrier (BBB) 
 The BBB is a tightly regulated barrier separating the brain parenchyma from the 
blood circulation. It plays a critical role in protecting the brain parenchyma from 
neurotoxic factors. The BBB is composed of endothelial cells connected by tight 
junctions and adhesion molecules (42–47). The abluminal side of the endothelial cell 
layer is surrounded by the basement membrane, which is made up of extracellular matrix 
proteins secreted by endothelial cells and adjacent astrocytes (48) (Figure 1.3). 
Pericytes, also on the abluminal side, are closely associated with the endothelial layer. 
They help regulate endothelial junctions and BBB permeability (49–51). The outermost 
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Figure 1.3 Schematic illustration of the BBB. 
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layer of the BBB is composed of astrocytic end-feet from neighboring astrocytes. The 
astrocytic end-feet form a second layer, abluminal to the endothelial layer, known as the 
glia limitans layer. This second layer creates the perivascular space between the 
endothelial layer and the glia limitans layer. Besides physically forming a barrier around 
the vessels, astrocytes also help maintain the BBB by regulating the electrical resistance 
and permeability of the BBB (52). They also secrete factors to regulate interactions 
between endothelial cells and pericytes (53). 
Besides functioning as a physical barrier, the endothelial cells also express 
selective drug transporters that regulate brain parenchyma molecule influx and efflux. 
Many different drug transporters are expressed on the BBB, including the P-gp 
(MDR1/ABCB1), the breast-cancer-resistance protein (BCRP/ABCG2), and the MRP1 
(ABCC1) (54, 55). Both P-gp and MRP1 are ATP-binding cassette transporters (ABC 
transporters), which use energy generated from ATP binding and hydrolysis to actively 
transport drugs out of the brain parenchyma (54, 55). Interestingly, P-gp and MRP1 are 
also highly expressed on GB, and they promote GB chemoresistance by actively 
pumping out chemotherapeutic drugs (56–58). However, because damage or 
inflammation in the CNS may have detrimental effects, it is critical for the BBB to 
restrict neurotoxic factors from entering the brain parenchyma. Unavoidably, this makes 
therapeutic drug delivery extremely difficult and hinders treatment for many CNS 
diseases. For example, diseases such as the Alzheimer's disease, Parkinson's disease, 
epilepsy, and brain tumors, can all benefit from having efficient drug delivery across 
the BBB to improve current treatments (54). In GB, the BBB in GB is not intact because 
its vessels are highly proliferative and often lack the proper CNS vessel integrity. 
Although studies have shown BBB disruption in GB (59, 60), clinically, therapeutic 
drugs cannot efficiently penetrate the tumor (61). For this reason, many studies are 
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exploring new ways of delivering drugs to GB (62). 
Regulation of BBB Permeability by Adenosine Signaling 
CD73 is naturally expressed in the central nervous system (CNS). Cells in the 
CNS, including astrocytes, microglia, pericytes and neurons, generate extracellular 
adenosine under normal physiological conditions to regulate sleep, arousal, 
neuroprotection, learning and memory, cerebral blood circulation, and neural 
transmission (43). Additionally, although endothelial cells forming the BBB in the CNS 
express low CD73 under physiological conditions, we demonstrated that adenosine 
signaling regulates BBB permeability (43). We previously showed that CD73-/- mice 
were resistant to experimental autoimmune encephalomyelitis (EAE) (63). Multiple 
sclerosis and EAE (its animal model) are debilitating, neuroinflammatory disorders of 
the CNS that are mediated by lymphocyte entry into the CNS. In addition to 
extracellular adenosine’s role in down-modulating inflammation, it also has the 
potential to stimulate the migration of immune cells. We showed that extracellular 
adenosine promoted lymphocyte migration into the CNS through the induction of the 
chemokine/adhesion molecule CX3CL1 at the choroid plexus (64). Additionally, CD73 
was required for efficient lymphocyte migration into the CNS during EAE (38). We 
showed that immune cells were unable to efficiently breach the BBB and cause EAE in 
the absence of CD73 (38). Moreover, broad spectrum AR antagonists, such as caffeine, 
or A2A AR specific antagonists protected wild type (WT) mice from EAE development 
by preventing lymphocyte infiltration in the brain and spinal cord (63). Therefore, to 
define the role of the A2A AR in EAE development, our lab induced EAE in the 
A2AAR−/− mice and found that they developed a more severe form of EAE compared to 
WT mice (38). This increased severity in EAE was a result of the increased pro-
inflammatory response mounted by A2AAR−/− leukocytes, which overcame any 
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inhibition of leukocyte infiltration provided by the lack of A2A AR signaling within the 
CNS (38). 
Not only did we show that the CD73-AR axis regulates leukocyte migration into 
the CNS, we also demonstrated that the FDA-approved selective A2A AR agonist 
Lexiscan (Regadenoson) increased the BBB permeability in murine models. We showed 
that A2A AR signaling temporally and dose-dependently increased the BBB 
permeability (65) (Figure 1.4). We also showed that the broad-spectrum AR agonist 
NECA increased anti-β-amyloid antibody delivery into the CNS in a transgenic mouse 
model of Alzheimer's disease (65). These findings suggest that BBB permeability can 
be modulated in vivo through activation or inhibition of AR signaling to promote 
therapeutic compound delivery into the CNS. To better understand the mechanism 
behind A2A AR signaling at the BBB, we investigated whether P-gp was regulated 
through A2A AR signaling. We found that the multidrug resistance transporter P-gp 
expressed on brain endothelial cells blocked drug delivery to the brain parenchyma (66). 
Further, we found that activation of the A2A AR with Lexiscan rapidly increased the 
BBB permeability and that this increased permeability was reversible (67). Together, 
these studies suggest that modulating the CD73-AR axis has the potential to block 
harmful immune cells entry into the brain and to deliver chemotherapeutic agents to 
treat diseases ranging from brain tumors to Alzheimer’s disease. 
CD73 and Its Implications in Cancer 
Besides regulating the BBB, CD73 is also involved in immune modulation, 
promotion of angiogenesis, and regulation of angiogenic and hypoxic genes (38–41). 
Because of these properties, CD73 and adenosine have been implicated in many cancers, 
including breast cancer, bladder cancer, leukemia, glioma, melanoma, ovarian cancer,
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Figure 1.4 Adenosine modulation of BBB permeability.  
Endothelial cells lining the brain vasculature express ARs, CD39, and CD73. In the 
presence of cell stress/inflammation or tissue damage, ATP is released and is rapidly 
converted to ADP and AMP by CD39; AMP is converted to adenosine by CD73. 
Adenosine binds to its receptor/s (A1 or A2A) on BBB endothelial cells, the activation of 
which induces reorganization of the actin cytoskeleton in BBB endothelial cells, 
resulting in tight and adherent junction disassembly and increasing paracellular 
permeability.
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thyroid cancer, esophageal cancer, gastric cancer, colon cancer, and prostate cancer (68–
77). CD73 expression is used as a diagnostic parameter in papillary thyroid cancer and 
is associated with increased metastasis in breast cancer and melanoma (78). CD73 
promotes cancer cell proliferation and migration (78–80). In breast cancer, CD73 
increases tumor metastasis and promotes angiogenesis (81–84). It has also been shown 
that melanoma in CD73-/- mice grew slower and was less malignant (85). Therefore, 
CD73 is a highly desirable target for cancer therapy, and inhibiting CD73 has the 
potential to improve treatment for multiple types of cancers. 
CD73 and Adenosine Regulation of Cancer Immune Response 
Adenosine Regulates Leukocyte Response Through Adenosine Receptor Signaling 
Adenosine was first implicated in the regulation of anti-tumor immunity by the 
Blay group in 1994 (86–91). They showed that extracellular adenosine concentration is 
10 to 20 times higher in tumor microenvironments compared to healthy tissues (90). 
This high extracellular adenosine concentration inhibited T cell and NK cell anti-tumor 
immune responses (86, 88, 89). It was later demonstrated by multiple groups that 
adenosine signaling through the A2A AR is the main pathway that regulates the 
attenuation of inflammation (92–94). The A2A AR is expressed on most leukocytes (95), 
including monocytes (96), macrophages (97), dendritic cells (98, 99), mast cells (100), 
neutrophils (100–102), lymphocytes (103–105), NK cells (106), and NKT cells (107). 
It is also found on endothelial and epithelial cells (95). Therefore, extracellular 
adenosine signaling through the A2A AR regulates a wide range of leukocytes and elicits 
a broad anti-inflammatory effect. 
ARs are G protein-coupled receptors and are composed of seven transmembrane 
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α-helices with an extracellular N-terminus and an intracellular C-terminus. The A1 and 
A3 ARs primarily couple with the Gi protein and the A2A and A2B AR primarily couple 
with the Gs protein. Adenosine binding to its receptor results in a conformational change 
in ARs. This change induces an interaction between the receptor and its G protein. The 
Gi protein-coupled A1 and A3 ARs inhibit downstream adenylate cyclase activity and 
reduce cyclic-AMP (cAMP) production. Conversely, the Gs protein-coupled A2A and 
A2B ARs excite downstream adenylate cyclase and increase cAMP production. cAMP 
acts as a secondary messenger that activates protein kinase A (PKA), which will then 
phosphorylates the cAMP response element binding protein (CREB) and regulates gene 
expression. 
Depending on where the A2A AR is expressed, A2A AR signaling attenuates 
inflammation through different pathways. In macrophages, activation of the A2A AR 
leads to increased cAMP, which activates PKA. Activated PKA phosphorylates CREB, 
which then leads to the transcription of the CRBPβ gene. Increased CRBPβ protein binds 
to the IL10 gene promoter and increases macrophage IL-10 production (108). In 
regulatory T (Treg) cells, they express CD73 on their cell surface and generate 
extracellular adenosine, which acts through both the autocrine and the paracrine 
pathways. Activation of the A2A AR on Treg cells upregulates their transcription factor 
Foxp3 and further enhances their ability to suppress inflammation (108). Without A2A 
AR expression, the anti-inflammatory properties of Treg cells would be reduced (109). 
A2A AR activation on effector T (Teff) cells is critical in regulating T cell activation. T 
cell receptor (TCR) signaling is required for Teff cell activation. When a TCR interacts 
with its antigen, a zeta chain of T cell receptor associated protein kinase 70 (ZAP70) is 
recruited and binds to the TCR. This TCR binding changes the conformation of ZAP70 
and results in its phosphorylation (110). This then leads to activation of the downstream 
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transcription factor activator protein 1 (AP1) and activation of T effector cells. However, 
A2A AR signaling in Teff cells inhibits ZAP70 phosphorylation; therefore, it inhibits 
TCR signaling and Teff cell activation. A2A AR signaling leads to decreased Teff cell 
proliferation and decreased T helper 1 (TH1), TH2, and TH17 lymphocyte development 
(108). Furthermore, A2A AR signaling on Teff cells promotes cytotoxic T-lymphocyte-
associated antigen 4 (CTLA4) and programmed cell death 1 (PD1) expression (108). 
All of these effects induced by A2A AR signaling significantly dampen the inflammatory 
response. 
While it is necessary to attenuate inflammation after clearing an infection to 
maintain immune homeostasis, this inhibitory effect is often used by cancer cells to 
evade the anti-tumor immune response. Understanding how CD73/adenosine signaling 
attenuates the anti-GB immune response will allow us to block or inhibit 
CD73/adenosine signaling in order to induce a stronger anti-GB immune response in 
GB patients. 
Host Immune Response to GB and How GB Evades the Immune Response 
Inflammation in the CNS 
 The CNS contains neuronal networks that are critical for survival and needs to 
be protected from excessive inflammation. Because the brain is enclosed by the skull, 
excessive leukocyte infiltration can cause swelling and an increase in intracranial 
pressure, damaging the CNS (111). Some pro-inflammatory molecules, including TNF-
α and IL-1, induce neurotoxic activities in the CNS (112–114). Therefore, inflammation 
in the CNS can result in neuronal death. To protect the CNS from inflammation-derived 
neurodegeneration, CNS-infiltrating leukocytes are absent in normal physiological 
conditions. 
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Host Immune Response to GB 
 Chen and Mellan proposed the Cancer-Immunity Cycle, which is composed of 
seven sequential steps that lead to an effective immune response to cancer (115). First, 
cancer antigen must be released (step 1) and presented by antigen-presenting cells 
(APC) (step 2). Then, tumor-specific T cells need to be activated by APC (step 3) and 
travel to the tumor site (step 4). Finally, these T cells must infiltrate the tumor (step 5), 
recognize the tumor antigen-MHC complex (step 6), and elicit cytotoxic effector 
functions to remove the cancer cells (step 7). Killing the cancer cells will produces more 
cancer antigen for antigen presentation by APCs, which amplifies the subsequent 7-step 
cycle. 
 In GB, tumor antigen is often released through two main pathways. First, GB 
antigen is released from necrotic tumor cells. Necrosis almost always occurs in GB, and 
clinically, pseudopalisading necrosis is a GB diagnosis feature (116). Therefore, 
spontaneous necrotic cell death constantly releases tumor antigens into the tumor 
microenvironment. Second, GB therapeutic treatments, such as chemotherapy, 
radiotherapy, and surgical removal of the tumor, all lead to tumor-antigen release (117). 
These tumor antigens are then taken up by macrophages, microglia cells, or dendritic 
cells located in meninges, perivascular space, or the choroid plexus epithelium and 
stroma (118, 119). Cells in the brain perivascular space and meninges are able to sample 
antigens inside the cerebrospinal fluid (CSF) (117). Additionally, during CNS 
inflammation, APCs infiltrate the brain parenchyma (117), increasing tumor-antigen 
presentation to T cells. 
 Activated GB-specific T cells then travel to the CNS by two main routes. T cells 
travel to meningeal vessels and enter the brain parenchyma by crossing the subarachnoid 
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space (117). T cells also travel to the postcapillary venules, cross the BBB, enter the 
perivascular space formed by astrocytic end-feet, and then cross the glia limitans layer 
into the brain parenchyma (120). 
In GB patients, 72.6% of newly diagnosed patient samples and 83.3% of 
recurrent patient samples showed tumor infiltrating lymphocytes (121). GB-infiltrating 
lymphocytes include CD8+ T cells, CD4+ T cells, and Treg cells. They make up about 
17% of all GB-infiltrating leukocytes (122), while approximately 30% of all GB-
infiltrating leukocytes are macrophages and microglia (123–125). Out of the GB-
infiltrating lymphocytes, about 25% are CD3+ T cells (122). Around 11% of GB-
infiltrating T cells are CD8+ T cells and 20% are CD4+ T cells (125). Of the CD4+ T 
cells, between 50 and 96% are positive for Foxp3, indicating that they are mostly Treg 
cells (122, 125). 
GB-infiltrating T cells elicit different immune responses in GB. The main role 
of CD8+ cytotoxic T cells in tumors is to recognize the tumor antigen-MHC I complex 
and induce cancer cell death through the release of granzyme B and perforin. CD4+ TH1 
cells interact with the antigen-MHC II complex on local APCs and secrete 
immunomodulatory cytokines, such as IFN-γ and TNF-α, to activate macrophages and 
NK cells. On the other hand, Foxp3+ Treg cells secrete IL-10 and TGF-β to suppress the 
inflammatory response to tumors. Whether the tumor escapes the host immune response 
is often determined by whether Teff cells successfully kill tumor cells. Because of the 
high Foxp3+ Treg cell infiltration in GB, the cytotoxic T cell response to GB is often 
ineffective, and GB thrives under the highly attenuated immune microenvironment. 
GB Immune Evasion Strategies 
 GB renders the anti-tumor immune response ineffective through multiple means. 
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One mechanism induces immune tolerance to GB through immune suppression by Treg 
cells. Most GB-infiltrating Treg cells are natural Treg cells (126), which are generated 
in the thymus and recruited to the GB site by the chemokine CCL2. Additionally, GB 
supports Treg cell expansion and survival through secretion of soluble factors that 
promote preferential Treg cell proliferation (127). Treg cells inhibit the immune 
response through production of anti-inflammatory cytokines, including IL-10 and TGFβ. 
Treg cells suppress CD4+ and CD8+ T cell activation and proliferation and reduce their 
inflammatory cytokine IL-2 and IFNγ production (128). Treg cells also express CD73 
and generate extracellular adenosine to inhibit inflammation through A2A AR signaling 
(108). 
GB cells can also hijack the peripheral tolerance mechanism to eliminate GB-
infiltrating T cells. This method of T cell elimination was first described in melanoma 
in 1993 (129, 130). The Fas receptor (Fas), also called Apo-1 or CD95, is a programmed 
cell death receptor that promotes apoptosis in self-reactive lymphocytes (131). Fas 
ligand (FasL) expression was found on melanoma cells and Fas+ T cells were found in 
the microenvironment in FasL+ melanoma (129). FasL+ melanoma cells induced Fas+ T 
cell apoptosis, and melanoma development was delayed in Fas-deficient mice (129). It 
was later found that, similar to melanoma, GB cells also express FasL, and apoptotic 
Fas+ T cells were found in proximity to FasL+ GB cells (132). Moreover, Fas+ T cells in 
GB are 8 times more susceptible to apoptosis than Fas- T cells (133), suggesting that the 
FasL+ GB cells are inducing T cell apoptosis. 
 In addition to inducing T cell apoptosis through FasL, GB also induces apoptosis 
through indoleamine 2,3 dioxygenase 1 (IDO1). 90% of human GB expresses IDO1 
(134), which is an enzyme that catabolizes the essential amino acid tryptophan into 
kynurenine. IDO1 expression in GB is negatively correlated with patient survival (135). 
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Tryptophan is critical for cell cycle progression in activated T cells (136). In the absence 
of tryptophan, the cell cycle of activated T cell halts at mid-G1 phase, and these cells 
become susceptible to apoptosis (136). Studies have also found that tryptophan 
metabolites suppress T cell proliferation and induces apoptosis independent of IDO1 
(137, 138). Furthermore, GB-expressed IDO1 is required for Treg recruitment in GB 
(139). Overall, these studies showed that IDO1 expression on GB cells inhibited the 
anti-tumor immune response by inducing T cell apoptosis and promoting Treg cell 
recruitment. 
 Immune checkpoint molecules, such as CTLA-4 (CD152) and PD-1 
(CD279)/PDL-1, are also used by GB to evade the immune response. CTLA-4 is 
expressed on T cells, and it competes with CD28 for the APC co-stimulatory molecules 
B7-1 (CD80) and B7-2 (CD86) (140). The ratio of CD28:B7 binding to CTLA-4:B7 
binding on T cells determines whether they will become activated (140). CTLA-4 
expression on T cells is negatively correlated with GB patient outcomes (141). 
Treatment with an anti-CTLA-4 antibody in a murine glioma model resulted in long-
term survival in 80% of treated mice (142). Unlike CTLA-4, which competes for APC 
co-stimulatory molecules, PD-1 on activated lymphocytes binds to PDL-1 expressed on 
tumor cells or APCs (143). (144–146). This binding suppresses T cell activation and 
inhibits T cell cytotoxic functions (143–145). It also induces anti-inflammatory cytokine 
IL-10 production and inhibits the pro-inflammatory cytokine production of IFN-γ, IL-
2, and TNFα (143–145). PDL-1 expression on glioma is strongly associated with World 
Health Organization (WHO) tumor grades, with a high PDL-1 expression in high grade 
GB and a low PDL-1 expression in low grade glioma (147). Whether GB directly 
induces lymphocyte CTLA-4 and PD-1 expression is currently unclear; however, 
CTLA-4 and PD-1/PDL-1 are key players in GB immune evasion. 
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 Another major hurdle for the immune system to clear GB is myeloid-derived 
suppressor cells (MDSCs). Terminally differentiated myeloid cells, including 
macrophages, dendritic cells, and neutrophils, can become MDSCs in tumor 
environments (148). MDSCs suppress the anti-tumor immune response by producing 
anti-inflammatory cytokines, including TGFβ (149, 150), and inducing the activation 
and expansion of Treg cells (151, 152). They also secrete nitric oxide (NO) and reactive 
oxygen species (ROS) and suppress T cell functions through arginase activity (153). 
GB-associated microglia and macrophages are the most abundant cell types of all GB-
infiltrating immune cells (154, 155), making them the dominant GB-infiltrating MDSCs. 
It has been shown that GB stem cells secrete periostin to recruit anti-inflammatory GB-
associated macrophages (156). These GB-associated macrophages/microglia have 
reduced phagocytic activity (157) and increased production of IL-10 and TGFβ (157). 
They also downregulate the co-stimulatory molecules CD80 and CD86, limiting their 
ability to induce T cell activation (158). Overall, MDSCs help GB maintain an immune 
suppressive environment and further inactivate other GB-infiltrating leukocytes. 
Current Immunotherapy and Challenges for GB Immunotherapy 
 Currently, immunotherapy against melanoma and non-small-cell lung cancer 
has shown remarkable results, successfully increasing patient survival (159–164). This 
was achieved mostly through the targeting of immune checkpoints using anti-CTLA-4 
and anti-PD-1/PDL-1 antibodies (159–164). Unfortunately, the same result did not 
happen in GB patients. The PD-1 antibodies pembrolizumab and nivolumab did not 
show clinical efficacy in recurrent GB patients in two separate clinical studies (165, 
166). Similarly, CheckMate-143 Phase I and III clinical trials using a nivolumab and 
ipilimumab (anti-CTLA-4 antibody) combination treatment in recurrent GB did not 
show improved overall patient survival compared with nivolumab treatment alone (167). 
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The Phase I clinical trial showed that nivolumab alone was well tolerated, while the 
toleration of the combination therapy with nivolumab and ipilimumab was dependent 
on the dose of ipilimumab (168). However, the Phase III clinical trial showed that 
nivolumab did not improve overall patient survival compared with approved 
bevacizumab (anti-VEGF-A antibody) treatment (169). Currently, clinical trials 
CheckMate-498 and CheckMate-548 using nivolumab in newly diagnosed GB patients 
are still ongoing. 
 One potential reason why PD-1 antibody therapy failed in recurrent GB patients 
is the BBB. Generally, only compounds smaller than 400-600 Da are able to cross the 
BBB, and cytokine-induced neutrophil chemoattractant-1 (7.8 kDa) was the largest 
compound found to cross the BBB through transmembrane diffusion (170). Because 
nivolumab has a calculated molecular mass of 146 kDa, it is plausible that it cannot 
cross the BBB to target GB-infiltrating PD-1+ cells directly, and only targeting PD-1+ 
cells in the periphery before they enter the CNS (171). This may dramatically decrease 
the efficacy of nivolumab in patients (172). Another possibility is that recurrent GBs 
are likely to contain a large pool of terminally differentiated T cells that were exhausted 
due to chronic exposure to GB antigens. Terminally differentiated exhausted T cells 
sometimes do not recover from PD-1:PDL-1 blockade (173); therefore, nivolumab 
treatment may not be ideal for recurrent GB. 
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Synthesis 
 The studies presented in this dissertation describe the role of host CD73 and the 
adenosine signaling pathway in GB pathogenesis and show the mechanism behind 
CD73 regulation of the host anti-tumor immune response. In Chapter 2, we 
demonstrate that host CD73 promotes GB pathogenesis using the GL261 syngeneic 
mouse model. In the absence of host CD73, GB size and invasiveness are reduced. We 
show that host CD73 promotes invasion by upregulating MMP9 along the tumor edge 
and inhibiting the MMP9 inhibitor TIMP1. Host CD73 also promotes GB angiogenesis. 
In the absence of host CD73, MMP2, VEGF, and α-dystroglycan are all upregulated, 
which results in increased glomeruloid vessels and reduced vessel density in GB-
bearing CD73-/- mice. This suggests that host CD73 is required for promoting mother 
vessels division into smaller vessels. Furthermore, we demonstrate that blockade of A2B 
AR signaling on mouse GL261 GB cells results in reduced chemoresistance to the 
chemotherapeutic drug temozolomide. 
 In Chapter 3, we demonstrate that host CD73 promotes GB immune evasion. 
We show that CD73 promotes anti-inflammatory microglia and macrophage GB-
infiltration and cytokine CCL22 production. This leads to increased T regulatory cell 
recruitment to the CNS and further attenuates the anti-tumor immune response. 
Therefore, GB-bearing CD73-/- mice show an increase in CD8+ T cell infiltration and a 
reduction in Treg cell recruitment. We also demonstrate that CD73 promotes leukocyte 
entry to the brain parenchyma by inducing them to cross the glia limitans layer formed 
by astrocyte end feet in GB-bearing mice. 
 In Chapter 4, we will summarize our findings, present our conclusions, and 
suggest future directions. 
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CHAPTER 2 
 
CD73 PROMOTES GLIOBLASTOMA PATHOGENESIS AND ENHANCES ITS 
CHEMORESISTANCE VIA A2B ADENOSINE RECEPTOR SIGNALING 
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Abstract 
Glioblastoma (GB) is one of the deadliest brain cancers to afflict humans, and it 
has a very poor survival rate even with treatment. The extracellular adenosine-
generating enzyme CD73 is involved in many cellular functions that can be usurped by 
tumors, including cell adhesion, proliferation, invasion, and angiogenesis. We set out to 
determine the role of CD73 in GB pathogenesis. To do this, we established a unique GB 
mouse model (CD73-FLK) in which we spatially expressed CD73 on endothelial cells 
in CD73-/- mice. This allowed us to elucidate the mechanism of host CD73 versus GB-
expressed CD73 by comparing GB pathogenesis in WT, CD73-/-, and CD73-FLK mice. 
GB in CD73-/- mice had decreased tumor size, decreased tumor vessel density, and 
reduced tumor invasiveness compared with GB in WT mice. Interestingly, GBs in 
CD73-FLK mice were much more invasive and caused complete distortion of the brain 
morphology. We showed a 20-fold upregulation of the A2B AR on GB compared with 
sham, and its activation induced matrix metalloproteinase-2, which enhanced GB 
pathogenesis. Inhibition of A2B AR signaling decreased multidrug resistance transporter 
protein expression, including the permeability glycoprotein (P-gp) and the multidrug 
resistance-associated protein 1 (MRP1). Further, we showed that blockade of A2B AR 
signaling potently increased GB cell death induced by the chemotherapeutic drug 
temozolomide. Together, these findings suggest that CD73 and the A2B AR play a 
multifaceted role in GB pathogenesis and progression and that targeting the CD73–A2B 
AR axis can benefit GB patients and inform new approaches for therapy to treat GB 
patients. 
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Significance Statement 
Glioblastoma (GB) is the most devastating primary brain tumor. GB patients’ 
median survival is 16 months even with treatment. It is critical that we develop 
prophylaxes to advance GB treatment and improve patient survival. CD73-generated 
adenosine has been implicated in cancer pathogenesis, but its role in GB was not 
ascertained. Here, we demonstrated that host CD73 plays a prominent role in multiple 
areas of glioblastoma pathogenesis, including promotion of GB growth, angiogenesis, 
and invasiveness. We found a 20-fold increase in A2B adenosine receptor (AR) 
expression on GB compared with sham, and its inhibition increased GB 
chemosensitivity to temozolomide. These findings strongly indicate that blockade or 
inhibition of CD73 and the A2B AR are prime targets for future GB therapy. 
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Introduction 
 Glioblastoma (GB) is the most common and most fatal primary malignant brain 
tumor (1) due to its high capacity to proliferate and its extreme chemoresistance (2). 
Further, the impermeability of the blood-brain barrier (BBB) makes chemotherapeutic 
drug delivery challenging for GB treatment (3). Currently, the median survival for GB 
patients is 16 months even with treatment (4). 
In this report, we investigated the role of the surface enzyme CD73 (ecto-5’-
nucleotidase) in GB pathogenesis as CD73 and its product, extracellular adenosine, have 
been implicated in the progression of other types of tumors (5–8). CD73 is a key enzyme 
in the adenosine triphosphate (ATP) metabolic pathway. In damaged tissues, ATP is 
released into the extracellular space (9, 10) and converted to adenosine diphosphate 
(ADP) and adenosine monophosphate (AMP) by the surface enzyme CD39 
(ectonucleoside triphosphate diphosphohydrolase-1); AMP is further converted to 
adenosine by CD73. 
Adenosine is a purine nucleoside that promotes tumor proliferation and 
angiogenesis (6, 11). To elicit its function, adenosine signals through four G-protein 
coupled receptors, A1, A2A, A2B, and A3. The A2B adenosine receptor (AR) has a very 
low affinity for adenosine and is activated under high, usually pathological, extracellular 
adenosine concentrations (in the µM range) (12–15), whereas the A1 AR has the highest 
affinity and is activated under basal adenosine concentrations (16, 17). Adenosine 
signaling through the A2B AR modulates tumor apoptosis and proliferation and the 
tumor immune microenvironment (13, 18–20). 
CD73 and adenosine are involved in tumor adhesion, invasion, proliferation, 
angiogenesis, and chemoresistance (6, 7, 11, 21–27). For example, under hypoxic 
  
 42 
conditions, upregulation of the hypoxia-inducible factor 1 (HIF-1) transcription factor 
increases CD73 generation of extracellular adenosine (11). Adenosine signaling through 
the A2A and A2B ARs induces the release of vascular endothelial growth factor (VEGF), 
which induces proliferation of endothelial cells and angiogenesis to promote tumor 
growth (11). CD73 and AR signaling also regulate matrix metalloproteinases (MMPs) 
(6, 25), which play crucial roles in angiogenesis and tumor invasion by degrading the 
extracellular matrix (ECM) (6). MMP2 and MMP9 have been shown to promote GB 
angiogenesis and invasion and to regulate vascular patterning (26, 27). However, how 
CD73 regulates GB pathogenesis and whether host CD73 contributes to tumor 
pathogenesis have not been elucidated. We hypothesized that GB usurped the host and 
its own CD73 (GB-CD73) to promote its growth and survival. To test this, we used 
unique mouse models lacking CD73 or expressing CD73 on endothelial cells to study 
GB pathogenesis. Our data revealed that both the host and GB-CD73 were key 
contributors to GB pathogenesis. These studies provide a potential target for GB 
therapeutic intervention through modulation of CD73 and/or CD73-AR axis.
  
 43 
Materials and Methods 
Cell culture 
GL261 and U251 cell lines were obtained from the National Cancer Institute and 
cultured in DMEM (10-013-CV, Cellgro; Corning) or RPMI 1640 (10-040-CM, 
Cellgro; Corning) respectively, with 10% fetal bovine serum, 100 units/ml penicillin 
and streptomycin at 37ºC/5% CO2 in a humidified incubator. Medium was changed 
every 2-3 days and cells were used when grown to confluency. 
Mice 
C57BL/6 mice were purchased from Jackson Laboratories. CD73−/− mice have been 
described previously (28) and were backcrossed to C57BL/6 mice for more than 14 
generations. Mice expressing CD73 primarily on endothelial cells (CD73-FLK mice) 
were produced by generating mice expressing murine CD73 under the control of the 
Flk-1 promoter (see details below) and crossing them to CD73-/- mice. All mice used in 
this study were males and age-matched. Mice were housed in specific-pathogen-free 
rooms until they were 8 weeks of age and moved to a broken barrier/biosafety level 2 
room for experiments in the mouse facility at Cornell University. Animal studies were 
approved by the institutional animal care and use committee of Cornell University 
(protocol no. 2008–0092). 
Generation of CD73-FLK mice 
Full-length CD73 was amplified by PCR from a murine CD73 plasmid (29) to add a 
consensus Kozak sequence and flanking restriction sites and then cloned into a plasmid 
containing promoter and intronic enhancer sequences from the murine Flk-1 gene (30) 
(a gift from Dr. Lijun Xia, Oklahoma Medical Research Foundation) using NheI and 
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EcoR I restriction sites. All plasmids were verified by sequencing. The full-length 5.4 
kb transgene was released by digesting this plasmid with SalI and XmaI and, after 
purification, was injected into C57BL/6 blastocysts at the University of North Carolina 
Animal Models Core Facility. The presence of the transgene was verified by PCR using 
the following primers: CD73Tg forward: 5’-GGGCGGATCAAGTTCTCTGCAGC-3’; 
CD73Tg reverse: 5’-TTAACTGGGACTGGGGC-AAAGTC-3’. Transgene-positive 
mice were bred to cd73-/- mice to generate offspring that expressed CD73 only under 
the control of the Flk-1 promoter. 
GB implantation 
GL261 and GL261CD73low cells were suspended in saline (15,000 cells/μl) and kept on 
ice. Mice were anesthetized with ketamine-xylazine (100 mg/kg) and ketoprofen (2 
mg/kg) was administered as an analgesic. Eye ointment was applied before hair 
removal. The scalps were sterilized by wiping three times with chlorhexidine solution 
followed by 70% ethanol. A midsagittal incision was made through the scalp and the 
bregma was located. A small hole was drilled 0.1 mm posterior and 2.3 mm lateral of 
the bregma. Then, 30,000 GL261 cells or saline (2 μl, sham) were injected 3 mm from 
the brain surface using a 27-gauge needle with a Hamilton syringe. The wound was 
closed using sutures and ketoprofen (2 mg/kg) was administered the day after surgery. 
Tissue harvest 
Mice were anesthetized with ketamine-xylazine and transcardial perfusion with ice-cold 
PBS was performed. Brains were cut coronally in half, flash frozen in Tissue-Tek 
optimal cutting temperature medium (Sakura Finetek), and stored at -80ºC. Brains were 
sectioned to 8 or 10 μm thick with a microtome, collected on Supefrost/Plus slides 
(Fisher Scientific), fixed in acetone, and stored at -80ºC.  
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Hematoxylin and eosin staining 
Frozen sections were fixed with acetone, stained with 0.1% hematoxylin and 0.5% eosin 
and mounted with Eukitt quick hardening mounting reagent. 
Invasion score 
GB invasion scores were measured using 20X scanned whole-brain images of H&E-
stained brain sections taken by Aperio CS2. GB invasion scores were the sum of the 
meninges invasion score, the invasion area score, and the invasion distance score. The 
meninges invasion score equaled the ceiling of the percentage of meninges invaded 
divided by 5 (to transform the percentage into a score ranging from 0 to 10). The 
invasion area score equaled the area of tumor-infiltrating non-neoplastic area divided 
by the total area of the tissue section (31). The invasion distance score equaled the 
ceiling of the displacement (in μm) between the farthest point of the tumor infiltrating 
non-neoplastic area and the tumor edge (32) divided by 500 (to transform the 
displacement into a score ranging from 0 to 10). 
Flow cytometry 
GL261 and GL261CD73low cells were stained with PE-conjugated antibody against mouse 
CD73 (1:200, 12-0731-83; eBioscience) and/or FITC-conjugated antibody against 
mouse CD44 (1:200, 553133; BD Biosciences), and U251 cells were stained with FITC-
conjugated antibody against human CD73 (1:200, 344015; BioLegend). Cells were then 
washed twice with 0.5% BSA/PBS. Brain tissues were collected from GB-bearing WT 
mice 3 weeks after implantation. Tumors were removed with a blade and homogenized 
with a Dounce homogenizer in RPMI 1640 (10-040-CM, Cellgro; Corning) with 10% 
fetal bovine serum. Tumor homogenates were centrifuged at 450 g for 10 minutes and 
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pellets were resuspended in 30% Percoll underlaid with 70% Percoll. Cells were 
centrifuged at 600 g for 20 min at room temperature and the layer at the 70% and 30% 
Percoll junction was collected and washed with 0.5% BSA/PBS. Red blood cells were 
lysed with ACK lysing buffer (A1049201; Thermo Fisher Scientific) according to the 
manufacturer’s protocol. Cells were blocked with anti-CD16/CD32 antibody (1:200, 
14-0161-85; eBioscience) and stained with PE-conjugated antibody against mouse 
CD73 (1:200, 12-0731-83; eBioscience). For intracellular staining, cells were fixed with 
4% paraformaldehyde (15710; Electron Microscopy Sciences) for 20 minutes, 
permeabilized with 0.1% saponin (A18820; Alfa Aesar) for 15 minutes, and then stained 
with PE-conjugated antibody against mouse CD73 (1:200, 12-0731-83; eBioscience) in 
0.1% saponin (A18820; Alfa Aesar). Cells were analyzed with BD Biosciences 
FACSCanto II. Laser configurations were as follows: GL261 – FSC 176 V, SSC 313 V, 
PE 493 V, FITC 533 V; U251 – FSC 176 V, SSC 313 V, FITC 533 V; Tumor 
homogenate – FSC 335 V, SSC 410 V, PE 400 V. Data were analyzed using FlowJo 
software version 10. 
Immunostaining 
For immunohistochemistry staining, slides were immersed in 0.3% H2O2 for 10 min to 
inactivate peroxidases. After two PBS washes, slides were blocked at room temperature 
with casein (Vector Laboratories) and 10% goat serum. Slides were then incubated 
overnight with primary antibody against CD31 (1:30, 550274; BD Pharmingen), MMP9 
(1:200, AB19016; Millipore), MMP2 (1:500, MAB3308; Millipore), or CD73 (1:100, 
BD Pharmingen, 550738) followed by two PBS washes. Slides were then incubated 
with HRP-conjugated secondary antibody, washed, and developed with an AEC 
substrate kit (Zymed) and stained with hematoxylin. Slides were mounted with 
Fluoromount-G. For immunofluorescence staining, slides or cells grown on coverslips 
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were blocked the same way as immunohistochemistry staining. For Ki-67 staining, 
slides were permeabilized using Foxp3 staining buffer set (00-5523-00; eBioscience) 
following the manufacturer’s protocol. Slides or coverslips were incubated overnight 
with primary antibody against CD73 (1:100, 550738; BD Pharmingen), CD133 (1:200, 
ab19898; Abcam), Ki-67 (1:50, 550609; BD Pharmingen), GFAP (1:500, 556330; BD 
Pharmingen), NeuN (1:200, 12943S; Cell Signaling), A1 AR (1:100, AAR-006; 
Alomone Labs), A2A AR (1:100, AAR-002; Alomone Labs), A2B AR (1:100, SC-7507; 
Santa Cruz), A3 AR (1:100, AAR-004; Alomone Labs), VEGFA (1:200, ab46154; 
Abcam), CD31 (1:30, 550274; BD Pharmingen), alpha-dystroglycan (1:100, 05-298; 
Millipore), MMP9 (1:200, AB19016; Millipore; 1:100, ab38898; Abcam), TIMP1 
(1:500, ab86482; Abcam), MMP2 (1:500, MAB3308; Millipore), P-gp (1:100, 
GTX23364; GeneTex), or MRP1 (1:100, ab32574; Abcam) followed by two PBS 
washes. Slides were then incubated with fluorophore-conjugated secondary antibody, 
washed, and mounted with ProLong Gold with DAPI. Slides were imaged with Zeiss 
Axio Imager.M1 with Zeiss Plan-Neofluar 20X objective (44 03 40). 
Sorting GL261CD73low cells 
GL261 cells were stained with PE-conjugated antibody against mouse CD73 (1:200, 
12-0731-83; eBioscience) and washed twice with 1% fetal bovine serum/PBS. Cells 
were sorted by BD Biosciences FACSAria II with the following laser configurations: 
FSC 250 V, SSC 160 V, PE 550 V. Data were analyzed using FlowJo software version 
10. Sorted cells were collected in 50% fetal bovine serum in DMEM (10-013-CV, 
Cellgro; Corning) and cultured as normal until confluent. CD73 expression of sorted 
GL261CD73low cells was analyzed by flow cytometry one day before implantation in 
mice. 
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Survival study 
GB-bearing mice were monitored by their weight loss. They were euthanized once they 
lost 20% of their pre-GB implantation weight. 
Isolation of primary mouse astrocytes 
Primary mouse cerebellar astrocytes were isolated following Current Protocols in 
Neuroscience – Isolation and Purification of Primary Rodent Astrocytes (33). Briefly, 
cerebella of p4 neonatal C57BL/6 mice were ground with a Dounce homogenizer, 
centrifuged through 30% and 60% Percoll gradients, and astrocytes were enriched at the 
medium and 30% Percoll interphase. Differential adhesion was performed to enrich the 
astrocyte population. Primary astrocytes were cultured in DMEM (10-013-CV, Cellgro; 
Corning) with 10% fetal bovine serum and 100 units/ml penicillin/streptomycin at 
37ºC/5% CO2 in 6-well plates or on coverslips in 96-well plates in a humidified 
incubator until confluent. Primary astrocytes were stained with the astrocyte marker 
GFAP and the neuronal marker NeuN following the immunofluorescent staining 
protocol to verify that they were GFAP-positive and NeuN-negative. 
Western blotting 
Protein concentrations of GL261 and U251 whole-cell lysates and brain tissue 
homogenates from sham or GB-implanted mice were measured with the Dc Protein 
Assay (Bio-Rad); 5 μg of samples were loaded onto an 8% or 10% SDS acrylamide gel 
and separated for 1 hour. Samples were transferred to a nitrocellulose membrane and 
then blocked with 1% BSA/tris-buffered saline with Tween 20 (TBST). Membrane was 
incubated with antibodies against A1 AR, A2A AR, A2B AR, A3 AR, P-gp, CD73, and 
VEGFA (1:2000, AAR-006, AAR-002, AAR-003, AAR-004; Alomone Labs; 1:1000, 
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GTX108354; GeneTex; 1:2000, AP2014b; Abgent; 1:1000, ab46154; Abcam, 
respectively) overnight at 4°C. Membrane was then washed three times with TBST and 
incubated with HRP-conjugated secondary antibody for 1 hour at room temperature. 
Following three TBST washes, the membrane was developed using Super Signal West 
Pico ECL solution (Thermo Scientific) and imaged with a Konica SRX-101A Medical 
Film Processor. Densitometry analysis was performed using ImageJ software. CD73 
protein expression inside the GB was measured by subtracting the CD73 protein level 
of sham-implanted WT or CD73-/- coronal brain sections from the CD73 protein level 
of GB-implanted WT or CD73-/- coronal brain sections. 
Vessel density and glomeruloid vessel quantification 
Brain sections were stained for CD31-positive vessels following the 
immunohistochemistry staining protocol described above. Vessel density was 
quantified by manually counting the number of CD31-positive vessel per area (1.5 
mm2). Glomeruloid vessels were identified by their multiple lumens in the thickened 
vessel wall and quantified by manually counting the number of glomeruloid vessels per 
area (1.5 mm2). 
Quantitative real-time PCR 
Brain mRNA was extracted with TRIzol reagent (Invitrogen) and cDNA was 
synthesized with High-Capacity cDNA Reverse Transcription Kits (Applied 
Biosystems) according to the manufacturers’ protocols. qRT-PCR was performed with 
specific primers (sequences included below) and KAPA SYBR FAST qPCR Kit (KAPA 
Biosystems) according to manufacturer’s protocol. qRT-PCR was done on Bio-Rad 
CFX96 Real-Time System C1000 Thermal Cycler. Gene expression levels were 
analyzed using GAPDH as a reference gene and normalized to controls using the 2–ΔΔCT 
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method (34). The following qRT-PCR primers were used: mouse MMP9 forward 5’-
GCCCTGGAACTCACAC-GACA-3’ and reverse 5’-TTGGAAACTCACACGCCAG-
AAG-3’; mouse MMP2 forward 5’-AAGGATGGACTCCTGGCACATGCCTTT-3’ 
and reverse 5’-ACCTGTGGGCTTG-TCACGTGGTGT-3’; mouse TIMP1 forward 5’-
CCAGAGCCGTCACTTTGCTT-3’ and reverse 5’-AGGAAAAGTAGACAGTGTT-
CAGGCTT-3’; mouse TIMP2 forward 5’-ACGCTTAGCATCACCCAGAAG-3’ and 
reverse 5’-TGGGACAGCGAGTGAT-CTTG-3’; human Pgp forward 5’-GCTCCTG-
ACTATGCCAAAGC-3’ and reverse 5’-TCTTCACCTCCAGGCTCAGT-3’; mouse 
GAPDH forward 5’-CATGGCCTTCCG-TGTTCCTA-3’ and reverse 5’-GCGGCAC-
GTCAGAT-CCA-3’; and human GAPDH forward 5’-GGTGGTCTCCTCTGACTTC-
AACA-3’ and reverse 5’-GTTGCTGTAG-CCAAATTCGTTGT-3’. 
MMP activity measurement 
MMP activity was measured according to the manufacturer’s protocol using the 
SensoLyte 520 Generic MMP Assay Kit (AS-71158; AnaSpec). Briefly, the A2B AR 
antagonist-treated GL261 cells were collected in assay buffer and brain tissues from 
sham or GB-implanted mice were homogenized in assay buffer and centrifuged to 
remove debris. Protein concentrations were measured with the Dc Protein Assay (Bio-
Rad); 400 μg of protein from each brain sample and 55.7 μg of protein from each A2B 
AR antagonist-treated GL261 sample were incubated with MMP substrate (fluorescence 
resonance energy transfer peptide) for 1 hr at room temperature in darkness. 
Fluorescence intensity was measured at Ex/Em = 490 nm/520 nm with BioTek Synergy 
4. Concentrations of cleaved MMP substrate were calculated by a standard curve and 
normalized to sham-implanted CTs. 
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A2B AR agonist and antagonist treatment on GB cell lines 
GL261 and U251 cells were grown in 6- or 12-well plates until confluent. Culture 
medium was replaced with an A2B AR agonist (BAY 60-6583, Torcis Bioscience) or 
antagonist (PSB 603; Torcis Bioscience) diluted in culture medium at concentrations 
tested to have an optimal inhibition effect for the GL261 and U251 cells (0.1, 10, or 100 
μM), or DMSO for 24 hours. Cells were washed twice with PBS, then lysed with 1% 
Igepal CA-630 lysis buffer or with TRIzol (Invitrogen) to collect protein or mRNA for 
Western blotting or qRT-PCR analysis. 
Rhodamine 123 (rho-123) uptake assay 
GL261 cells were grown in 96-well plates or coverslips until confluent and were treated 
with rho-123 (2.5 μM) and DMSO or PSB 603 (10 to 400 μM) for 4 to 24 hours. Cells 
were then washed with ice-cold PBS to remove extracellular rho-123. Cells in 96-well 
plates were lysed with 1% Igepal CA-630 lysis buffer to measure rho-123 and protein 
concentration with BioTek Synergy 4. Cells on coverslips were fixed and stained with 
anti-P-gp antibody following the immunofluorescence staining protocol. 
GL261 temozolomide (TMZ) survival assay 
GL261 cells grown in 12-well plates were treated with DMSO (0.54%), TMZ (30 μM), 
PSB 603 (100 μM), and TMZ (30 μM) + PSB 603 (100 μM) for 72 hours. TMZ stock 
was prepared by dissolving TMZ in DMSO (20 g/ml). Both adherent cells and cells in 
suspension were collected and stained with 4% Trypan blue, and viable/dead cell 
numbers were counted with a hemocytometer. 
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Experimental design and statistical analysis 
All mice used in this study were age-matched male mice assigned randomly into sham 
or GB-implanted groups. All statistical analyses were performed on GraphPad Prism 
6.0 software. P values were calculated using either one-way ANOVA followed by 
Bonferroni’s post hoc test, two-way ANOVA followed by Tukey’s post hoc test, or an 
unpaired 2-tailed Student’s t test. A p-value of less than 0.05 was considered significant. 
Immunofluorescent intensity quantifications were performed using Zen software. 
Positive pixel count analyses were performed using ImageScope analysis program. 
Densitometry analysis for Western blot results were performed using ImageJ software. 
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Results 
GB cells express CD73 and upregulates their own CD73 in CD73-/- mice. 
 To investigate whether GB expressed CD73, we first quantified CD73 
expression in vitro on glioma cell lines. Both mouse GL261 and human U251 glioma 
cell lines expressed CD73 at 30.4% and 93.4%, respectively (Figure 2.1A and B; SD = 
13.45 and 13.46 respectively). Because CD44 is commonly expressed on GL261 cells, 
it was used as an additional marker for GL261 identification. We observed that 9.2% of 
GL261 cells coexpressed CD44 and CD73 (Figure 2.1C; SD = 1.43). We then 
intracranially implanted mouse GL261 glioma cells or saline (sham) into wild-type 
(WT) or CD73-/- mice to determine whether host CD73 contributed to GB pathogenesis 
or if CD73 expression on GB (GB-CD73) alone was sufficient to promote GB 
pathogenesis.  
Sham-implanted and naïve WT mice expressed abundant CD73 in specific brain 
regions, especially the caudoputamen (Figure 2.1D, E; p < 0.0001, t = 20.04, df = 16, t 
test, G, and H; p < 0.0001, t = 38.42, df = 15, t test) but not in other areas such as the 
cortex (Figure 2.1D and F; p = 0.2544, t = 1.185, df = 16, t test). This was compared 
with the absence of CD73 in sham-implanted and naïve CD73-/- mice (Figure 2.1D, E; 
p < 0.0001, t = 20.04, df = 16, t test, G, and H; p < 0.0001, t = 38.42, df = 15, t test). 
More importantly, GB-CD73 was significantly upregulated in GB-bearing CD73-/- mice 
(Figure 2.1I and J; p = 0.0399, t = 2.236, df = 16, t test). We also calculated the GB-
CD73 protein level by subtracting the GAPDH normalized CD73 level in brain tissue 
in sham WT or CD73-/- mice from the GAPDH normalized CD73 level in respective 
GB-bearing mice and compared the fold change over sham WT mice (Figure 2.1K; p 
= 0.004, t = 6.399, df = 7, t test). We found a significant increase in GB-CD73 in CD73-
  
 54 
/- mice compared with WT mice (Figure 2.1K; p = 0.004, t = 6.399, df = 7, t test). To 
investigate whether GB-CD73 was expressed on the cell surface, we performed flow 
cytometry analysis on tumor cells isolated 3 weeks after GB implantation and found a 
similar percentage of CD73+ GB cells from both the permeabilized and non-
permeabilized cell populations (Figure 2.1L; p = 0.096, t = 2.168, df = 4, t test). 
However, the median fluorescent intensity (MFI) was significantly increased in 
permeabilized GB cells (Figure 2.1M and N; p = 0.003, t = 6.415, df = 4, t test). This 
indicated that CD73 was expressed both on the cell surface and in the cytoplasm of 
CD73+ GB cells. The increased GB-CD73 expression in GB-bearing CD73-/- mice 
suggests that GB either upregulates GB-CD73 expression to compensate for the absence 
of host CD73, or that CD73-expressing GB cells are positively selected in the absence 
of host CD73. This is critical because it suggests that CD73 plays a substantial role in 
GB pathogenesis and that host CD73 contributes to GB pathogenesis. 
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Figure 2.1
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Figure 2.1. GB expresses CD73 in vitro and upregulates CD73 in CD73-/- mice in 
vivo. A, B, Representative flow cytometry analysis of CD73 expression on GL261 (A) 
and U251 (B) GB cell lines. Data are representative of three experiments. C, 
Representative flow cytometry analysis of CD44 and CD73 expression on GL261. Data 
are representative of three experiments. D, G, Representative images of sham-implanted 
(D) and naive (G) mice brain sections stained with anti-CD73 antibody (brown) (n = 3). 
E, F, H, Quantification of CD73 expression in caudoputamen or cortex of sham-
implanted or naive mice was performed by measuring positive pixel count using 
ImageScope analysis program (n = 3, three images analyzed/sample, Student’s two-
tailed t test). I, Representative images of brain sections from GL261-implanted mice 
stained with anti-CD73 antibody (brown) (n = 3– 4). J, Quantification of CD73 
expression inside tumors was performed by measuring positive pixel count using 
ImageScope analysis program (n = 3– 4, 3 images analyzed/sample, Student’s two-
tailed t test). K, Densitometry quantification of CD73 protein expression inside tumors 
using ImageJ, normalizing to GAPDH and sham CTs (n = 4 –5, Student’s two-tailed t 
test). L, M, N, Flow cytometry analysis of CD73 expression percentage (L) (n = 3, 
Student’s two-tailed t test), histogram (M), and median fluorescent intensity 
quantification (N) (n = 3, Student’s two-tailed t test) on disassociated tumors from GB-
bearing WT mice 3 weeks after implantation (n = 3, Student’s two-tailed t test). Data 
are shown as mean ± SEM. *p < 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p < 0.0001.
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Host CD73 promotes GB growth and invasiveness. 
To test the hypothesis that host CD73 promotes GB pathogenesis, we harvested 
brains from GB-bearing WT and CD73-/- mice and quantified GB size 17 days or 3 
weeks after GB implantation. GB cells were identified by nuclear atypia, such as nuclear 
enlargement, pleomorphism, and hyperchromasia. The tumor border was defined as a 
distinct area that distinguishes between the non-neoplastic tissue and the GB tissue. GB 
tissue also showed distinctive tissue discoloration under H&E staining, making the 
tumor edge easy to identify. We found that WT mice consistently harbored significantly 
larger tumors compared with CD73-/- mice 3 weeks after implantation (Figure 2.2A and 
B; p = 0.0130, t = 2.960, df = 11, t test); this was despite the increase in GB-CD73 in 
CD73-/- mice, indicating that GB-CD73 cannot fully compensate for the lack of host 
CD73. GB size at day 17 after implantation also showed a similar, though not 
significantly different, trend of reduced GB size in CD73-/- mice at this time point 
(Figure 2.2C and D; p = 0.58, t = 0.59, df = 4, t test). In addition to the size difference, 
the tumors in WT mice were more invasive 3 weeks after implantation; they penetrated 
the meninges and invaded other non-neoplastic areas, whereas GBs in CD73-/- mice 
remained mainly at the site of GB implantation (Figure 2.2A). Because GBs generally 
do not metastasize but tend to invade surrounding tissues (characterized by tumor cells 
infiltrating non-neoplastic areas (35)), we scored GB invasion based on meningeal 
invasion percentage, invasion area percentage, and distance from the invaded cells to 
the edge of the tumor (31, 32). GBs in CD73-/- mice were significantly less invasive 3 
weeks after implantation (Figure 2.2A and E; p = 0.0003, F (2, 28) = 10.77, ANOVA), 
suggesting that despite increased GB-CD73, the lack of host CD73 critically hindered 
GB invasiveness in CD73-/- mice. 
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Vascular expression of CD73 increases GB invasiveness. 
To investigate how host CD73 promoted GB invasiveness in WT mice, we 
generated a CD73-FLK mouse model in which we enforced CD73 expression under the 
flk promoter (Figure 2.2F) that was specific for endothelial cells in CD73-/- mice. 
Alexiades et al. (36) have shown that flk is expressed on neuronal stem cells; therefore, 
we double stained naïve CD73-FLK brain tissue with the stem cell marker CD133 and 
CD73. However, we did not observe CD73 expression on neuronal stem cells in CD73-
FLK mice (Figure 2.2G). We confirmed CD73 expression on the vasculature in CD73-
FLK mice by immunohistochemical staining (Figure 2.2H). CD73 was observed on 
vascular structures in areas such as the dentate gyrus in CD73-FLK mice, but not in WT 
mice (Figure 2.2H), because WT endothelial cells do not express detectable levels of 
CD73 in vivo (37, 38). Because GB naturally tends to invade along vascular beds (39, 
40) and host CD73 promotes GB invasiveness, we hypothesized that increased host 
CD73 along the vascular beds would further enhance GB invasiveness. Indeed, we 
found that GBs in CD73-FLK mice were significantly more invasive than GBs in WT 
mice at both 17 days and 3 weeks after implantation (Figure 2.2A, C, E; p = 0.0003, F 
(2, 28) = 10.77, ANOVA, and I; p = 0.0288, F (2, 6) = 6.783, ANOVA). This indicates 
that host CD73 expression on the vasculature significantly increases GB invasion when 
it is the only source of host CD73. 
Host CD73 contributes more significantly to GB growth and invasiveness than GB-
CD73. 
 To investigate whether GB-CD73 contributes to GB growth and invasiveness in 
addition to host CD73, we sorted GL261 mouse glioma cells and selected only CD73-
negative cells (referred to as GL261CD73low) for implantation (Figure 2.2J). 
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GL261CD73low cells were cultured until confluent and were implanted into WT or CD73-
/- mice (cells were 98.4% CD73-negative at the time of implantation (Figure 2.2K). 
Three weeks after implantation, brain tissues from GB-bearing mice were analyzed by 
H&E staining. We found that tumors from GL261CD73low-implanted CD73-/- mice were 
significantly smaller than those from GL261CD73low-implanted WT mice (Figure 2.2L 
and M; p = 0.0379, t = 3.052, df = 4, t test). Despite the difference in tumor size between 
WT and CD73-/- mice, the tumors were similar in size compared with their unsorted 
GL261-implanted counterparts (Figure 2.2B; p = 0.0130, t = 2.960, df = 11, t test). This 
suggests that host CD73 plays a greater role in promoting GB growth than GB-CD73. 
Interestingly, tumors from GL261CD73low-implanted WT and CD73-/- mice and unsorted 
GL261-implanted WT mice all had similar invasion scores (Figure 2.2E; p = 0.0003, F 
(2, 28) = 10.77, ANOVA, and N; p = 0.4167, t = 0.9050, df = 4, t test). This suggests 
that GB-CD73 does not contribute significantly to GB invasiveness in WT mice and 
that, in the absence of both GB-CD73 and host CD73, other pathways regulating GB 
invasiveness may be induced to promote GB pathogenesis.  
Absence of host CD73 prolongs the survival of GB-bearing mice. 
 To determine whether the reduction in GB size and invasiveness in GB-bearing 
CD73-/- mice is enough to increase survival in GB-bearing mice, we implanted GL261 
in WT, CD73-/-, and CD73-FLK mice; these mice were euthanized after they lost 20% 
of their initial weight. We found that GB-bearing CD73-/- mice had a significant increase 
in survival compared with GB-bearing CD73-FLK mice (Figure 2.2O; p = 0.0362, df 
= 2, log-rank test). This indicates that in the absence of host CD73, GB is less pathogenic 
and thus prolongs survival in GB-bearing mice. 
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Figure 2.2
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Figure 2.2. Host CD73 promotes GB growth and invasion. A, C, Representative 
H&E-stained brain sections from GL261- or sham-implanted mice 3 weeks after 
implantation (A) (n = 6–7 per group) or 17 d after implantation (C) (n = 3 per group). 
Solid black lines are tumor borders. B, E, Quantification of H&E-stained brain sections 
(n = 6–7 per group, Student’s two-tailed t test and one-way ANOVA, respectively). B, 
D, M, Tumor size is quantified by percentage of tumor area as follows: (tumor 
area/brain section area) X100. E, I, N, Tumor invasiveness was scored based on 
invasion area, invasion distance, and meningeal invasion. (D, I, M, N) (n = 3 per group, 
Student’s two-tailed t test for D, M, and N and one-way ANOVA for I ). F, Schematic 
of CD73-FLK mice transgene construct. FW, Forward; RV, reverse. G, Representative 
images of naïve CD73-FLK mice brain sections stained with anti-CD73 antibody (red), 
CD133 (green), and DAPI (blue) (n = 3). H, Representative images of sham-implanted 
WT and CD73-FLK mice brain sections stained with anti-CD73 antibody (brown) (n = 
3). J, CD73-negative gating used for sorting GL261 cells. K, Flow cytometry analysis 
of CD73 expression on GL261CD73low cells. L, H&E-stained brain sections from 
GL261CD73low-implanted mice 3 weeks after implantation (n = 3). Solid black lines are 
tumor borders. O, GL261-implanted mice survival (n = 5–9 per group, log-rank test). 
Data are shown as mean ± SEM. *p < 0.05.
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Absence of host CD73 inhibits GB angiogenesis and promotes glomeruloid vessel 
formation. 
Because GB size was significantly reduced in CD73-/- mice and angiogenesis is 
a key factor in regulating tumor growth, we next investigated whether host CD73 
regulated GB angiogenesis. We found a significant decrease in vessel density within the 
tumors of CD73-/- and CD73-FLK mice (Figure 2.3A and B; p < 0.0001, F (5, 37) = 
16.37, ANOVA). Interestingly, compared with WT mice, the vessel diameter and the 
number of glomeruloid vessels within the tumors were increased in CD73-/- and CD73-
FLK mice (Figure 2.2A, C; p =0.0140, F (2, 12) = 6.228, ANOVA, and D; p = 0.0036, 
F (2, 32) = 6.740 respectively, ANOVA). Because glomeruloid vessels are formed by 
highly proliferative endothelial cells (41), we investigated whether these GBs showed 
increased expression of the proliferation marker Ki-67. Indeed, Ki-67 expression was 
upregulated in glomeruloid vessels compared with non-glomeruloid vessels in GB 
(Figure 2.3E and F; p = 0.0001, t = 4.007, df = 91, t test). In addition to nuclear Ki-67 
staining, we also observed a high Ki-67 expression outside of the nucleus in glomeruloid 
vessels. Even though Ki-67 is mainly found in the nucleus, membrane and cytoplasmic 
Ki-67 expression have been found in other cancers, including breast cancer and 
laryngeal squamous cell carcinoma (42, 43). Therefore, the cytoplasmic Ki-67 
expression observed in glomeruloid vessels was likely real. This increase in Ki-67 
expression indicates that increased GB-CD73 in CD73-/- mice and increased host CD73 
on the vasculature in CD73-FLK mice promote intravascular endothelial cell 
proliferation. However, in the absence of the full complement of host CD73 (such as in 
WT mice), proliferating endothelial cells cannot adequately form new vessels, 
suggesting that both GB-CD73 and host CD73 regulate GB angiogenesis.  
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Figure 3
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Figure 2.3. Absence of host CD73 inhibits GB angiogenesis and promotes 
glomeruloid vessel formation. A, Representative images of brain sections from 
GL261- or sham-implanted mice stained with anti-CD31 antibody (brown) (n = 4–6 per 
GB-implanted group and n = 2 for sham-implanted group). B, Quantification of vessel 
number per area (1.5 mm2) (n = 3– 6 per GB-implanted group and n = 2 per sham-
implanted group, three images analyzed/sample, one-way ANOVA). C, Vessel diameter 
measured by ImageScope software (n = 4–6 per group, three images analyzed/sample, 
one-way ANOVA). D, Quantification of glomeruloid vessel number per area (1.5 mm2) 
(n = 3–5 per group, 10 vessels analyzed/sample, one-way ANOVA). E, Representative 
images of brain sections from GL261-implanted mice 3 weeks after implantation stained 
with anti-CD31 (green), anti-Ki-67 antibody (red), and DAPI (blue). Arrowheads 
indicate Ki-67 endothelial nuclear expression and arrows indicate the absence of Ki-67 
expression in endothelial nuclei (n = 3– 4 per group). F, Ki-67 mean fluorescent 
intensity (MFI) quantified using Zen image analysis program (n = 10, 3 images 
analyzed/sample, 3 areas analyzed/image, Student’s two-tailed t test). Data are shown 
as mean ± SEM. *p < 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p < 0.0001.
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Host CD73 promotes GB angiogenesis via regulation of VEGF and α-dystroglycan. 
We next investigated whether CD73 regulated angiogenesis-related factors that 
contributed to the dramatic differences observed in GB vessel phenotype between GB-
bearing WT and CD73-/- mice. We found that VEGF closely lined GB-associated blood 
vessels in CD73-FLK mouse (Figure 2.4A), supporting its role in GB angiogenesis. 
Further, we observed increased VEGF protein expression on GBs in CD73-/- mice 
(Figure 2.4B, C; p < 0.0001, F (3, 276) = 33.32, ANOVA, and D; p = 0.0084, F (3, 18) 
= 5.316, ANOVA), which could lead to intravascular proliferation and increased 
glomeruloid vessels. This also suggests that increased GB-CD73 in GB-bearing CD73-
/- mice promotes VEGF expression. However, the decreased vessel number indicates 
that host CD73 is critical for GBs to form vascular beds required for their growth and 
expansion. 
 The decrease in vessel density despite increased VEGF in GB-bearing CD73-/- 
mice was likely a result of reduced endothelial cell migration. Therefore, we next 
investigated the expression of α-dystroglycan. α-dystroglycan is a membrane receptor 
that tethers the basement membranes on vessels to endothelial cells and is involved in 
angiogenesis regulation, endothelial cell migration, and tube formation (44, 45). We 
observed a significant increase in α-dystroglycan expression around CD31+ endothelial 
cells inside GBs in CD73-/- mice compared with GBs in WT mice (Figure 2.4E and F; 
p < 0.0001, F (3, 61) = 32.05, ANOVA). This suggests that host CD73 inhibits α-
dystroglycan expression in GB and that increased α-dystroglycan and VEGF promotes 
glomeruloid vessel formation in GB. Further, reduction in α-dystroglycan expression is 
also associated with poor prognosis for human GB (46), suggesting that the absence of 
host CD73 leads to a an improved prognosis for GB patients. 
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Figure 2.4
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Figure 2.4. Host CD73 promotes GB angiogenesis via regulating VEGF and α-
dystroglycan. A, B, Representative images of brain sections from GL261- or sham-
implanted mice stained with anti-CD31 (green), anti-VEGF antibody (red), and DAPI 
(blue) (n = 4–5 per GB-implanted group and n = 2 per sham-implanted group). C, VEGF 
mean fluorescent intensity (MFI) quantified using Zen image analysis program (n = 4–
5 per GB-implanted group and n = 2 per sham-implanted group, 2– 6 images 
analyzed/sample, one-way ANOVA). D, Western blot densitometry analysis of VEGF 
(n = 5–7 per group, one-way ANOVA). E, Representative images of brain sections from 
GL261- or sham-implanted mice (3 weeks after implantation) stained with anti-CD31 
(green), anti-α-dystroglycan antibody (red), and DAPI (blue); images taken from inside 
the tumor (n = 3– 4 per GB-implanted group and n = 2 per sham-implanted group). F, 
α-dystroglycan MFI inside the tumor quantified using Zen image analysis program (n = 
3–4 per GB-implanted group and n = 2 per sham-implanted group, five areas 
analyzed/sample, one-way ANOVA). Data are shown as mean ± SEM. *p < 0.05, ****p 
< 0.0001.
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Host CD73 promotes GB angiogenesis and invasiveness through regulation of 
matrix metalloproteinases (MMPs).  
Because both angiogenesis and invasion require remodeling of the extracellular 
matrix, which is often performed by MMP activity, we next investigated whether CD73 
regulated MMPs and/or their inhibitors, tissue inhibitor of matrix metalloproteinases 
(TIMPs). We found MMP2 expression surrounding the vessels of GB, labeled by CD31 
(Figure 2.5A and B), and it was significantly higher in GB-implanted CD73-/- and 
CD73-FLK mice (Figure 2.5C; p <0.0001, F (2, 27) =16.87, ANOVA). Conversely, the 
MMP2 inhibitor TIMP2 mRNA expression was similar between CD73-/-, CD73-FLK, 
and WT GB-implanted mice (Figure 2.5D; p=0.3036, F (3, 22) = 1.287, ANOVA). This 
suggests that CD73 regulates MMP2 expression but not TIMP2 expression in GB and 
that increased GB-CD73 expression in a host with little or no CD73 promotes MMP2 
upregulation. 
We next examined MMP9 in WT and CD73-/- mice and found strong MMP9 
expression lining the tumor’s edge (Figure 2.5E, F, and G), which was consistent with 
its role in GB invasion. Interestingly, MMP9 expression at the edge of the tumor was 
highest in CD73-FLK mice (Figure 2.5H; p < 0.0001, F (2, 27) = 13.22, ANOVA), 
suggesting that the increased MMP9 contributed to the increased invasiveness observed 
in these mice (Figure 2.2A, C, E; p = 0.0003, F (2, 28) = 10.77, ANOVA, and H; p = 
0.0288, F (2, 6) = 6.783, ANOVA) and that host CD73 expression on endothelial cells 
increased MMP9 expression on the edge of GBs. Even more interestingly, the 
expression of the MMP9 inhibitor TIMP1 was significantly higher in GB-implanted 
CD73-/- mice (Figure 2.5G and I; p < 0.0001, F (2, 187) = 78.35, ANOVA). This 
indicates that host CD73 inhibits TIMP1 expression and that MMP9 activity was 
  
 69 
inhibited in GB-bearing CD73-/- mice, leading to decreased GB invasiveness (Figure 
2.2A and C, E; p = 0.0003, F (2, 28) = 10.77, ANOVA, and H; p = 0.0288, F (2, 6) = 
6.783, ANOVA). Moreover, TIMP1 expression was significantly lower in GB-bearing 
CD73-FLK mice compared with WT mice (Figure 2.5G and I; p < 0.0001, F (2, 187) 
= 78.35, ANOVA). This suggests that host CD73 expression on endothelial cells 
contributes greatly to TIMP1 inhibition and results in increased GB invasiveness in 
CD73-FLK mice (Figure 2.2A and C, E; p = 0.0003, F (2, 28) = 10.77, ANOVA, and 
H; p = 0.0288, F (2, 6) = 6.783, ANOVA). Furthermore, to determine whether MMP 
activity was altered in our GB models, we incubated tissue homogenates collected from 
sham and GB-implanted brain tissues with fluorescence resonance energy transfer 
(FRET) MMP substrate peptide as a MMP activity indicator. We found that MMP 
activity was significantly lower in homogenates from GB-bearing CD73-/- mice (Figure 
2.5J; p = 0.0465, df = 11, t = 2.242, t test). This indicates that, despite the increase in 
MMP2 expression, the overall MMP activity in GB-bearing CD73-/- mice is decreased 
compared with GB-bearing WT mice. This suggests that host CD73 regulates MMP 
activity in GB, increasing MMP9 expression and inhibiting TIMP1 to promote GB 
invasiveness. Therefore, increased GB-CD73 alone cannot compensate for the lack of 
host CD73 in regulating MMP activity. 
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Figure 2.5
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Figure 2.5. CD73 regulates MMP2, MMP9, and TIMP1 to promote GB 
invasiveness and angiogenesis. A, Representative images of brain sections from 
GL261- or sham-implanted mice (3 weeks after implantation) stained with anti-CD31 
(green), anti-MMP2 antibody (red), and DAPI (blue) (n = 3– 4 per GB-implanted group 
and n = 2 per sham-implanted group). B, Representative images of brain sections from 
GL261- or sham-implanted mice (3 weeks after implantation) stained with anti-MMP2 
antibody (brown) (n = 3– 4 per GB-implanted group and n = 2 per sham-implanted 
group). C, MMP2 immunohistochemistry staining positive pixel count was quantified 
using ImageScope analysis program (n = 3– 4 per group, three images analyzed/sample, 
one-way ANOVA). D, qRT-PCR analysis of TIMP2 mRNA collected from GL261- or 
sham-implanted mice (3 weeks after implantation) (n = 8 –11 per GB-implanted group 
and n = 2–3 per sham-implanted group, one-way ANOVA). E, Representative images 
of brain sections from GL261- or sham-implanted mice (3 weeks after implantation) 
stained with anti-MMP9 antibody (green) and DAPI (blue); images taken from the edge 
of the tumor (n = 3– 4 per GB-implanted group and n = 2 per sham-implanted group). 
F, Representative images of brain sections from GL261- or sham-implanted mice (3 
weeks after implantation) stained with anti-MMP9 antibody (brown) (n = 3–4 per GB-
implanted group and n = 2 per sham-implanted group). G, Representative images of 
brain sections from GL261- or sham-implanted mice (3 weeks after implantation) 
stained with anti-TIMP1 (green), anti-MMP9 antibody (red), and DAPI (blue); images 
taken from the edge of the tumor (n = 4–5 per GB-implanted group and n = 2 per sham-
implanted group). H, MMP9 immunohistochemistry staining positive pixel count on the 
tumor edge quantified using ImageScope analysis program (n = 3– 4 per group, three 
images analyzed/sample, one-way ANOVA). I, TIMP1 MFI in brain sections quantified 
using Zen image analysis program (n = 4 –5, three images analyzed/sample, one-way 
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ANOVA). J, MMP activity of brain tissue homogenates from GB-bearing mice (3 
weeks after implantation) normalized to sham-implanted CTs (n = 4 –7, Student’s two-
tailed t test). Data are shown as mean ± SEM. *p < 0.05, **p ≤ 0.01, ****p < 0.0001. 
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GB upregulates the A2B AR in vivo. 
To elucidate whether CD73 regulated GB pathogenesis through AR signaling, 
we first compared AR expression on GB with AR expression on mouse primary 
astrocytes from which the GB cells originated. The primary astrocytes we isolated 
expressed the astrocyte marker glial fibrillary acidic protein (GFAP), but not the 
neuronal marker (NeuN) (Figure 2.6A). GL261 cells in vitro expressed A1, A2A, and 
A2B AR proteins at levels similar to that of primary astrocytes, whereas the A3 AR was 
expressed at a much lower level (Figure 2.6B; p = 0.0002, t = 12.73, df = 4, t test). 
Similarly, the human U251 GB cells expressed all four adenosine receptors (Figure 
2.6C). When we examined AR expression on sham or GB-implanted mice brain 
sections, A1 and A3 AR expression were similar between sham mice and inside GB in 
both WT and CD73-/- mice (Figure 2.6D, E and G; p = 0.0043, F (3, 153) = 4.557, 
ANOVA). A2A AR expression was lower in GB-bearing CD73-/- mice, but it was not 
significantly different between GB and sham-implanted WT mice (Figure 2.6F and G; 
p = 0.0043, F (3, 153) = 4.557, ANOVA). However, we found that the A2B AR 
expression was significantly upregulated by almost 20-fold in GB compared with sham 
in vivo, whereas very little expression was found on astrocytes in sham-implanted mice 
stained with the astrocyte marker GFAP (Figure 2.6F; p = 0.0043, F (3, 153) = 4.557, 
ANOVA, and H). This indicates that astrocytes express very low levels of the A2B AR 
in vivo, whereas transformed GB cells highly upregulate the A2B AR in vivo. This is 
consistent with previous reports of low or diminished A2B AR expression under basal 
conditions (12). Because the A2B AR is often activated under pathological conditions 
with high extracellular adenosine concentrations (in the μM range) and it was highly 
upregulated in GBs in vivo, we further investigated the role the A2B AR plays in GB 
pathogenesis. 
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GB A2B AR signaling increases MMP2 mRNA expression and MMP activity. 
To investigate whether CD73 promoted GB MMP activity through A2B AR 
signaling, we treated mouse GL261 glioma cells with the A2B AR agonist BAY 60-6583 
and found that activation of the A2B AR upregulated MMP2 mRNA expression (Figure 
2.6I; p = 0.0040, F (2, 14) = 8.412, ANOVA). This suggests that the upregulation of 
GB-CD73 in CD73-/- mice (Figure 2.1J; p = 0.0399, t = 2.236, df = 16, t test) increases 
A2B AR signaling on GBs, which leads to increased MMP2 expression in GBs in CD73-
/- mice. We found no difference in MMP9, TIMP1, and TIMP2 mRNA levels in GL261 
cells upon A2B AR agonist treatment (Figure 2.6J; p = 0.8896, F (2,15) = 0.1178, 
ANOVA, K; p = 0.8343, F (2, 15) = 0.1834, ANOVA, and L; p = 0.2283, F (2, 15) = 
1.633, ANOVA). This suggests that the increased MMP9 in GB-bearing CD73-FLK 
mice and the increased TIMP1 in GB-bearing CD73-/- mice are not regulated by A2B AR 
signaling on GB cells. Because TIMP2 expression was not altered in vivo in GB-bearing 
CD73-/- mice or in vitro through A2B AR signaling on GBs, it is plausible that TIMP2 is 
not regulated by CD73. To determine whether changes in MMP2 mRNA expression 
induced by the A2B AR led to changes in MMP activity, we treated the mouse glioma 
cell line GL261 with the A2B AR antagonist PSB 603 and the FRET MMP substrate 
peptide as a MMP activity indicator. We found that the A2B AR antagonist significantly 
decreased GL261 MMP activity (Figure 2.6M; p = 0.0216, F (2, 15) = 5.010, ANOVA), 
suggesting that A2B AR signaling on GB cells contributed to the regulation of GB-MMP 
activity. 
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Figure 2.6
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Figure 2.6. GB upregulates A2B AR, and signaling through A2B AR promotes 
MMP2 expression on GB. A, Representative image of primary astrocyte stained with 
anti-GFAP antibody (red), anti-NeuN (green), and DAPI (blue). B, Densitometry 
quantification of ARs protein expression in GL261 cells and in primary mouse 
astrocytes using ImageJ and normalizing to GAPDH (n = 3, Student’s two-tailed t test). 
C, Western blot analysis of ARs on human U251 cells (n = 4). D–F, Representative 
images of brain sections from GL261- or sham-implanted mice (3 weeks after 
implantation) stained with anti-GFAP antibody (red), DAPI (blue), and anti-A1 AR 
(green) (D), anti-A3 AR (E), or anti-A2A AR (F) (n = 3–4 per group). G, Number of 
ARs per microscopic field (n = 3–8 per group, two-way ANOVA). H, Representative 
images of brain sections from GL261- or sham-implanted mice (3 weeks after 
implantation) stained with anti-A2B AR (green), anti-GFAP antibody (red), and DAPI 
(blue) (n = 5– 6 per GB-implanted group and n = 2 per sham-treated group). I–L, qRT-
PCR analysis of MMP2 (I), MMP9 (J), TIMP1 (K), and TIMP2 (L) mRNA from 
GL261 treated with BAY 60–6583 (n = 6, one-way ANOVA for I–L). M, MMP FRET 
activity of GL261 cells treated with BAY 60–6583 (n = 6, one-way ANOVA). Data are 
shown as mean ± SEM. *p < 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p < 0.0001.
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A2B AR signaling blockade downregulates GB multidrug resistance (MDR) 
transporter function and increases GB chemosensitivity. 
 GB is resistant to most chemotherapy partly because it highly expresses MDR 
transporters such as the P-glycoprotein (P-gp) and the multidrug resistance-associated 
protein (MRP1) (47) (Figure 2.7A and B), which expel chemotherapeutic drugs from 
tumor cells. Our lab has shown that activation of the A2A AR increases BBB 
permeability by modulating P-gp function in brain endothelial cells (48–50). Because 
P-gp, MRP1, and the A2B AR were all highly upregulated in GB in vivo (Figure 2.7C; 
p < 0.0001, F (3, 71) = 17.15, ANOVA, D; p < 0.0001, F (3, 77) = 28.34, ANOVA, 6F; 
p = 0.0043, F (3, 153) = 4.557, ANOVA, and G) and MRP1 and P-gp expression were 
significantly higher in GB in CD73-/- mice (Figure 2.7C; p < 0.0001, F (3, 71) = 17.15, 
ANOVA and D; p < 0.0001, F (3, 77) = 28.34, ANOVA), we hypothesized that signaling 
through the A2B AR induced the upregulation of P-gp and/or MRP1 in GB. Indeed, 
treatment of GL261 cells with an A2B AR-specific antagonist (PSB 603) dose-
dependently decreased both P-gp and MRP1 protein expression (Figure 2.7E; p = 
0.0002, F (2, 19) = 14.15, ANOVA and F; p = 0.0123, F (2, 6) = 9.980, ANOVA). 
Moreover, A2B AR antagonist treatment of U251 cells also resulted in a significant 
decrease in P-gp mRNA expression levels (Figure 2.7G; p = 0.0188, F (2, 5) = 9.748, 
ANOVA), indicating that A2B AR signaling regulated MDR transporters both in human 
and mouse GB. This suggests that the increased GB-CD73 in CD73-/- mice (Figure 
2.1J; p = 0.0399, t = 2.236, df = 16, t test) results in increased activation of the A2B AR, 
and thus increases P-gp and MRP1 in GB in CD73-/- mice (Figure 2.7C; p < 0.001, F 
(3, 71) = 17.15, ANOVA and D; p < 0.001, F (3, 77) = 28.34, ANOVA).  
To investigate whether inhibition of A2B AR signaling led to increased P-gp 
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substrate uptake, we concomitantly treated GL261 cells with the P-gp substrate 
rhodamine 123 (rho-123) and the A2B AR antagonist PSB 603 and measured 
intracellular rho-123 uptake (Figure 2.7H). We found that inhibition of the A2B AR led 
to increased intracellular rho-123 concentrations in the tumor cells (Figure 2.7I and J; 
p = 0.0277, t = 2.889, df = 6, t test), suggesting that inhibiting A2B AR signaling led to 
increased intracellular accumulation of P-gp substrate by downregulating P-gp 
expression. Because CD31+ endothelial cells in GBs strongly upregulated P-gp and 
MRP1 (Figure 2.7A and B), we hypothesized that GBs regulated MDR transporters on 
host endothelial cells by signaling through the A2B AR to promote GB chemoresistance. 
We found that inhibition of the A2B AR on primary mouse brain endothelial cells also 
downregulated P-gp expression (Figure 2.7K; p = 0.0414, F (2, 4) = 7.829, ANOVA), 
suggesting that increased extracellular adenosine level during pathological conditions 
(12), such as in the GB microenvironment, could potentially alter host endothelial cells 
of the BBB through the A2B AR and alter BBB permeability to promote 
chemoresistance. 
We next investigated whether A2B AR antagonist treatment increased GB 
sensitivity to chemotherapeutic drugs by treating GL261 cells with temozolomide 
(TMZ, 30 μM), a known P-gp substrate (51), in the presence or absence of A2B AR 
antagonist treatment for 3 days and then quantified the number of live/dead cells 
(Figure 2.7L). TMZ treatment alone did not increase the percentage of dead cells but 
decreased the total number of cells compared with controls (Figure 2.7M; p < 0.0001, 
F (3, 8) = 279.9, ANOVA, and N; p < 0.0001, F (3, 8) = 65.41, ANOVA). This indicated 
that GL261 cells were indeed resistant to TMZ-induced cell death, and that the reduction 
in cell numbers could be a result of decreased cell proliferation. However, cotreatment 
with TMZ and the A2B AR antagonist significantly increased GL261 cell death up to 
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95% (Figure 2.7M; p < 0.0001, F (3, 8) = 279.9, ANOVA), indicating that GB cells 
were more sensitive to chemotherapeutic drugs when A2B AR signaling was inhibited. 
These findings suggest that GB uses A2B AR signaling to upregulate P-gp and MRP1 
expression and to increase its chemoresistance. Together, these findings suggest that 
CD73 and the A2B AR are potential targets for GB treatment. 
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Figure 2.7
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Figure 2.7. A2B AR signaling promotes GB MDR transporter expression and 
enhances its chemoresistance. A, B, Representative images of brain sections from 
GL261- or sham-implanted mice (3 weeks after implantation) stained with anti-CD31 
(green) and anti-P-gp antibody (red) (A) or anti-CD31 (green) and anti-MRP1 antibody 
(red) (B) (n = 3– 4 per GB-implanted group and n = 2 per sham-implanted group). C, 
D, P-gp (C) and MRP1(D) MFI in brain sections quantified using the Zen image 
analysis program (n = 3– 4 per GB-implanted group and n = 2 per sham-implanted group, 
three images analyzed/sample, one-way ANOVA for C and D). E, F, Western blot 
densitometry analysis of P-gp (E) (n = 4 –10 per group) or MRP1 (F) (n = 2– 4 per 
group, one-way ANOVA for E and F) on GL261 treated with PSB 603. G, qRT-PCR 
analysis of P-gp mRNA from U251 cells treated with PSB 603 (n = 3, one-way 
ANOVA). H, Rho-123 uptake assay procedure. I, Quantification of rho-123 
concentration from GL261 cell lysate treated with PSB 603 (400 μM) relative to DMSO 
control (n = 4, Student’s two-tailed t test). J, GL261 treated with cell culture medium 
(no-treatment control), DMSO, or PSB 603 and rho-123 (green) for 4 h and stained with 
anti-Pgp antibody (red) and DAPI (blue) (n = 3). K, Western blot densitometry analysis 
of P-gp on primary mouse brain endothelial cells treated with PSB 603 or DMSO control 
normalized to GAPDH using ImageJ software (n = 2–3 per group, one-way ANOVA). 
L, GL261 chemotherapy sensitivity assay procedure. M, N, Cell death percentage (M) 
and live cell concentration (N) of GL261 cultured with DMSO control, TMZ (30 μM), 
PSB 603 (100 μM), or the latter two together for 72 h (n = 3, one-way ANOVA for M 
and N). Data are shown as mean ± SEM. *p < 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p < 
0.0001.
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Discussion  
Purinergic molecules such as adenosine are conserved across species and play 
critical roles in regulating cell survival and proliferation and mediating cell 
communication between glial cells and neurons in the CNS (52). Studies have suggested 
that adenosine plays a significant role in cancer development and progression by 
attenuating the immune response (5). However, these studies were not able to show how 
host and GB-CD73 affect GB pathogenesis and progression. In this report, we 
hypothesized that GBs used the purinergic enzyme CD73 to promote their growth and 
development. We further hypothesized that CD73-/- mice would produce smaller GBs 
compared with WT mice, with their full complement of host CD73. Indeed, GBs in 
CD73-/- mice were significantly smaller and less invasive. Further, we showed that GBs 
in CD73-FLK mice were much more invasive than GBs in WT mice. This observation 
aligns with our hypothesis that host CD73 promotes GB pathogenesis, including 
increasing its invasiveness. 
We observed that WT mice exhibited a high density of blood vessels within 
GBs, whereas GB-bearing CD73-/- mice had significantly fewer vessels. In addition, 
vessels in GB-bearing CD73-/- mice had enlarged lumens and increased glomeruloid 
vessel morphology. Glomeruloid vessels are surrounded by multiple layers of basement 
membrane and are poorly perfused (53). The decreased vessel density causes a reduction 
in vessel surface area to volume ratio and is likely to result in insufficient nutrient 
supply. In sporadic vestibular schwannoma, vessel density is positively correlated with 
tumor size and growth (54). We propose that the decreased vessel density and increased 
(layered) basement membrane, combined with insufficient nutrient supply, in GB-
bearing CD73-/- mice contributed to the decreased tumor size. 
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We observed increased VEGF expression in GB-bearing CD73-/- mice. 
Sundberg et al. have shown that VEGF delivered by adenovirus in the ears of a-thymic 
mice is sufficient to induce and maintain glomeruloid bodies similar to GB glomeruloid 
vessels (41). This suggests that the elevated VEGF expression seen in GB-bearing 
CD73-/- mice promotes endothelial cell proliferation and glomeruloid vessel formation. 
However, increased α-dystroglycan in GB-bearing CD73-/- mice, but not in WT mice, 
suggests that GB endothelial cells in CD73-/- mice are more tightly associated with the 
basement membrane. Therefore, their ability to migrate and form new vessels is limited. 
We propose that increased VEGF, which promotes endothelial cell proliferation, along 
with increased α-dystroglycan expression, which reduces endothelial cell migration, 
lead to glomeruloid vessel formation in GBs. 
In addition to VEGF and α-dystroglycan, MMP2 has been shown to regulate GB 
angiogenesis by promoting vascular branching (26). Although we observed increased 
MMP2 expression in GB-bearing CD73-/- mice, the overall MMP activity was decreased 
compared with GB-bearing WT mice. This suggests that, in the absence of host CD73, 
MMP activity decreased, resulting in reduced vascular branching and increased 
glomeruloid vessel formation. This also indicates that increased GB-CD73 is 
insufficient to promote angiogenesis in the absence of host CD73. 
The increased GB-CD73 in GB-bearing CD73-/- mice suggests that GB-CD73 
and host CD73 have overlapping roles in GB pathogenesis. When implanted in an 
environment lacking CD73, CD73-positive GB cells will be selected and/or GB cells 
will upregulate GB-CD73 to promote their survival. To investigate whether GB-CD73 
contributes to GB pathogenesis, we implanted GL261CD73low cells in WT and CD73-/- 
mice. Interestingly, GL261CD73low-implanted WT and CD73-/- mice did not show 
significant alterations in GB growth. This indicates that, although host CD73 and GB-
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CD73 may have overlapping roles in regulating GB pathogenesis, host CD73 
contributes more significantly to GB growth. 
The tumor microenvironment contributes significantly to tumor development, 
and host glial cells (astrocytes and microglia) are major producers of TIMPs, MMPs, 
and VEGF in the CNS (55–58). We investigated whether CD73 on host glial cells 
regulate extracellular matrix remodeling through MMPs and/or TIMPs to promote GB 
angiogenesis and invasion. We observed increased expression of the MMP9 inhibitor 
TIMP1 in GB-bearing CD73-/- mice. TIMP1 was observed mostly on the edge and 
outside the borders of GB. This suggests that TIMP1 is regulated by CD73 expressed 
on host cells. In addition, MMP9 expression was the highest in GB-bearing CD73-FLK 
mice and TIMP1 expression was the highest in GB-bearing CD73-/- mice, suggesting 
that they are both regulated by CD73. It has been shown that GB-associated microglial 
cells are the main contributors of MMP9 and not tumor cells (59). Therefore, because 
we could not find any alteration in MMP9 and TIMP1 expression by antagonizing the 
A2B AR on GB cells, it is more likely that host cells such as astrocytes and microglia 
are the main producers of MMP9 and TIMP1 in GB-bearing mice. Because MMP9 
expression is mostly observed at the tumor edge, it is likely that it is the host cells 
responding to the tumor and/or the interaction between GB cells and host cells that lead 
to increased MMP9 at the tumor edge. This further emphasizes the importance of host 
CD73 in GB pathogenesis. 
Additionally, because CD73 is a prominent immune regulator, the host immune 
response to GB may be significantly altered in CD73-/- mice. For instance, CD73-/- 
microglial cells do not become ramified when exposed to ATP (60), and this can 
significantly alter GB pathogenesis. Therefore, the upregulation of GB-CD73 in CD73-
/- mice could not fully compensate for the lack of host CD73 in the host environment. 
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We found increased GB P-gp and MRP1 expression in CD73-/- mice. GB cells 
were also more sensitive to chemotherapeutic drugs when GB A2B AR signaling was 
inhibited. We showed that A2B AR signaling in GB promotes GB chemoresistance by 
upregulating P-gp and MRP1. These data suggest that GB-CD73 is the main driver of 
GB MDR transporter expression and show that both host CD73 and GB-CD73 
contribute to GB pathogenesis independently. As a result, when using anti-CD73 
antibody or CD73 inhibitor as a treatment, it is important to know that the host and GB 
may respond to the treatment differently, and that targeting specific cells may help 
predict the treatment outcome. 
We showed that the A2B AR played a critical role in GB pathogenesis. The A2B 
AR has a low affinity for adenosine compared with other adenosine receptors, which 
further supports the hypothesis that the A2B AR is activated during high/pathological 
adenosine concentrations (12–15), such as during hypoxia and inflammation. This 
coincides with our findings of increased A2B AR in pathological GB conditions 
compared with sham mice, along with its involvement in regulating MMP activity and 
MDR transporters in GB. 
Based on these findings, we propose that GB uses host CD73 to increase MMP9 
expression and inhibit TIMP1 to promote GB invasion (Figure 2.8A). Host CD73 also 
promotes GB angiogenesis by increasing GB vessel number (Figure 2.8B). The absence 
of host CD73 leads to increased GB-CD73, VEGF, MMP2, and α-dystroglycan and 
results in the formation of glomeruloid vessels (Figure 2.8B). Finally, A2B AR signaling 
on GB cells promotes P-gp/MRP1 expression and increases GB chemoresistance 
(Figure 2.8C).  
GB is the deadliest of all brain tumors, with a median patient survival time of up 
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to 16 months, even with treatment (4). Here, we demonstrated multiple pathways of host 
and GB-CD73 contribution to GB pathogenesis, such as GB angiogenesis, invasion, and 
its chemoresistance. These studies indicate that modulating host CD73 and GB-
CD73/AR2B AR signaling may significantly improve treatment and increase the lifespan 
of GB patients. 
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Figure 2.8
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Figure 2.8. Working model describing how CD73 promotes GB pathogenesis. A, 
Host CD73 promotes GB invasiveness by upregulating MMP9 and inhibiting its 
inhibitor, TIMP1. B, Host CD73 upregulates angiogenesis by promoting mother vessels 
to divide into smaller vessels, thereby increasing the vessel density in GB (solid arrows). 
In the absence of host CD73, GB upregulates GB-CD73 and increases MMP2 
expression through A2B AR signaling. GB-CD73 promotes VEGF and α-dystroglycan 
expression, which leads to intravascular endothelial cell proliferation and glomeruloid 
vessel formation in GB (dotted arrows). C, CD73-generated adenosine acts via the A2B 
AR to promote P-gp and MRP1 upregulation, which results in increased drug efflux, 
thereby increasing GB chemoresistance
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CHAPTER 3 
 
HOST CD73 PROMOTES GLIOBLASTOMA EVASION OF HOST IMMUNE 
RESPONSE  
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Abstract 
 The adenosine-generating enzyme CD73 is a key immune regulator that 
attenuates inflammation and restores immune homeostasis. We set out to determine the 
role of CD73 in regulating the immune response to glioblastoma (GB), which is the most 
aggressive primary brain tumor. We intracranially implanted mouse GB cells in wild-
type (WT) and CD73-/- mice to determine the anti-GB immune response in the presence 
or absence of host CD73. We found that compared with GB-bearing WT mice, GB-
bearing CD73-/- mice mounted an overall stronger immune response. GB-bearing CD73-
/- mice had increased pro-inflammatory cytokine TNF-α, reduced T regulatory cell-
infiltration, increased cytotoxic T cell infiltration, and increased M1 microglia and/or 
macrophages. This reduction in T regulatory cell-recruitment was associated with 
reduction in the CCL22 chemokine and its receptor, CCR4, in GB-bearing CD73-/- mice. 
In addition, CD73-/- macrophages were intrinsically more pro-inflammatory compared 
with WT macrophages. CD73 also promoted leukocyte entry into the brain parenchyma 
by allowing them to cross the glia limitans layer and exit the perivascular space. These 
findings show that host CD73 attenuates anti-tumor immune responses and promots GB 
immune evasion. Taken together, inhibiting host CD73 may benefit patients by allowing 
them to elicit a stronger inflammatory response to GB, thereby increasing the potency 
of immunotherapy for GB patients. 
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Introduction 
The purinergic nucleoside adenosine is a primal immune-attenuating signaling 
molecule that exists in all life forms (1). It is the metabolic product of adenosine 
triphosphate (ATP). Extracellular ATP is metabolized into adenosine diphosphate 
(ADP) and adenosine monophosphate (AMP) via the surface enzyme ectonucleoside 
triphosphate diphosphohydrolase-1 (CD39); AMP is converted to adenosine via another 
surface enzyme ecto-5’-nucleotidase (CD73). Therefore, CD39 and CD73 regulate the 
ratio of extracellular ATP concentration to extracellular adenosine concentration. This 
balance of extracellular ATP and adenosine concentration is crucial to maintaining the 
immune homeostasis (2).  
The physiological extracellular ATP concentration is around 1 μM under basal 
conditions (3). However, upon infection (4) or tissue damage/stress (5), or under 
hypoxic/necrotic conditions (6, 7), cells release ATP into the extracellular space, 
increasing the extracellular ATP concentration to threefold or more (8). ATP can be 
passively released by necrotic cells or actively transported out by apoptotic or activated 
cells (8). This increase in extracellular ATP concentration often serves as a danger signal 
and promotes inflammatory responses to clear pathogens or damaged/apoptotic cells. 
Extracellular ATP signals through purinergic P2 receptors to induce inflammatory 
responses. For example, ATP induces the chemotaxis of inflammatory cells (9) and 
promotes the release of inflammatory cytokines (10) and oxygen free radicals (11). On 
the other hand, extracellular adenosine signaling provides a countermeasure to the often-
damaging inflammatory response and restores immune homeostasis. Adenosine reduces 
the release of pro-inflammatory cytokines (12) and promotes the production of the anti-
inflammatory cytokine IL-10 (13). It also inhibits immune cell recruitment by reducing 
chemokine secretion (14) and inhibiting endothelial cell adhesion molecule expression 
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(15). Besides attenuating inflammation, adenosine also promotes tissue repair and 
regeneration, including inducing fibrosis, wound healing, and angiogenesis to increase 
oxygen supply (16). Due to the potent immune-attenuating effects of adenosine, it has a 
short half-life and only lasts for less than 10 seconds in the extracellular environment 
(17, 18) before it is quickly converted to inosine by adenosine deaminase (ADA). Thus, 
the extracellular adenosine-generating enzyme CD73 is an important immune regulator 
that promotes anti-inflammatory immune responses and restores immune homeostasis. 
Interestingly, CD73 is expressed on many types of cancers including 
glioblastoma (GB) (19), bladder cancer (20), breast cancer (21), colon cancer (22), 
esophageal cancer (23), melanoma (24), ovarian cancer (25), prostate cancer (26), and 
thyroid cancer (27). We have previously shown that host CD73 promotes GB 
pathogenesis by increasing GB invasiveness, angiogenesis, and chemoresistance (28). 
Besides promoting GB pathogenesis, extracellular adenosine also has strong immune-
attenuating effects. Thus, we wanted to further investigate how CD73 contributed to the 
host anti-GB immune response. We hypothesized that in the absence of the host 
extracellular adenosine-generating enzyme CD73, the immune system would be able to 
mount a stronger inflammatory response against GB. This study allows us to elucidate 
the role host CD73 plays in the anti-GB immune response, and to determine whether 
targeting the CD73/adenosine signaling pathway has the potential to improve 
immunotherapy for GB patients.  
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Materials and Methods 
Cell Culture 
Mouse glioma cell line GL261 was obtained from the National Cancer Institute. Cell 
were cultured in DMEM with 10% fetal bovine serum (FBS) and 100 units/ml penicillin 
and streptomycin at 37ºC in a humidified incubator with 5% CO2. Media was changed 
every 2-3 days and cells were split or used for experiments when grown to confluency. 
Mice 
C57BL/6 mice were purchased from Jackson Laboratories. CD73−/− mice have been 
described previously (29) and were backcrossed to C57BL/6 mice for more than 14 
generations. Mice were housed in specific-pathogen-free rooms until 8 weeks of age and 
moved to a broken barrier/biosafety level 2 room for experiments in the mouse facility 
at Cornell University. Animal studies were approved by the Institutional Animal Care 
and Use Committee (IACUC) of Cornell University (protocol no. 2008–0092). 
GB implantation 
Mice were anesthetized with ketamine-xylazine (100mg/kg), and 2mg/kg of ketroprofen 
were administered as analgesic. Eye ointment was applied before the mice’s heads were 
shaved. The scalps were sterilized by wiping 3 times with chlorhexidine solution 
followed by 70% ethanol.  A midsagittal incision was made through the scalp and the 
bregma was located. A small hole was drilled 0.1mm posterior and 2.3 mm lateral of the 
bregma. 30,000 GL261 mouse glioma cells in 2 μl of saline were injected 3mm from the 
surface of the brain using a 27-gauge needle with Hamilton syringe. The wound was 
closed using suture and ketoprofen (2mg/kg) administered the day after surgery. 
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Tissue harvest 
Mice were anesthetized with ketamine-xylazine and transcardial perfusion with ice-cold 
PBS was performed. Brains were cut coronally in half, flash frozen in Tissue-Tek O.C.T. 
(Sakura Finetek), and stored at -80ºC. Brains were sectioned to 8 or 10 μm thick with a 
microtome, collected on Supefrost/Plus slides (Fisher Scientific), fixed in acetone, and 
stored at -80ºC.  
Immunostaining 
For immunohistochemistry staining, slides were air dried and immersed in 0.3% H2O2 
for 10 minutes to inactivate peroxidases. After two PBS washes, slides were blocked at 
room temperature with casein (Vector Laboratories) and 10% goat serum. Slides were 
then incubated overnight with primary antibody followed by two PBS washes. Slides 
were then incubated with HRP conjugated secondary antibody, washed, developed with 
an AEC substrate kit (Zymed), and stained with hematoxylin. Slides were mounted with 
Fluoromount-G and sealed with nail polish. For immunofluorescence staining, slides 
were blocked at room temperature with casein (Vector Laboratories) and 10% goat 
serum and incubated overnight with primary antibody followed by two PBS washes. 
Slides were then incubated with fluorophore conjugated secondary antibody, washed, 
and mounted with ProLong Gold with DAPI. 
Quantitative real-time PCR 
Brain mRNA was extracted with TRIzol (Invitrogen) and cDNA was synthesized with 
High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems) according to 
manufacturers’ protocol. RT-PCR was performed with specific primers and KAPA 
SYBR FAST qPCR Kit (KAPA Biosystems) according to manufacturer’s protocol. 
  
 100 
Gene expressions were analyzed using GAPDH as a reference gene and normalized to 
controls using the 2 –ΔΔCT method (30). 
Isolation of mouse primary peritoneal macrophages 
Mouse primary peritoneal macrophages were isolated following a protocol published by 
Fortier and Falk (31). Briefly, 1 ml of 3% Brewer thioglycollate medium was 
administered via intraperitoneal injection. Donor mice were euthanized 5 days after 
injection by CO2 asphyxiation and abdominal skins were retracted. 10 ml of harvest 
medium (DMEM with 5% FBS) per mouse was injected intraperitoneally using a 20 G 
needle and peritoneal fluid was withdrawn into the same syringe slowly. Cells were 
seeded in 12-well plates at a density of 4.5 x 105/well and grown to confluent before 
use.  
  
 101 
Results 
Host CD73 promotes anti-inflammatory immune responses to GB. 
 We have previously shown that GB pathogenesis is hindered in a host 
environment lacking CD73, and this leads to a reduction in GB size and invasiveness 
(28). Because of the potent anti-inflammatory properties of extracellular adenosine, we 
hypothesized that host CD73 also contributed to promoting GB pathogenesis by 
attenuating the anti-GB immune response. To test this, we intracranially implanted 
mouse GL261 glioma cells or saline (sham) into C57BL/6 wild-type (WT) and CD73-/- 
mice and collected their brain tissues after 3 weeks to determine whether anti-GB 
immune responses were altered in the CNS. We found that GBs were highly infiltrated 
by CD45+ leukocytes in both WT and CD73-/- mice (Fig. 3.1A). However, brain 
cytokine mRNA profiles from GB-bearing WT and CD73-/- mice were drastically 
different. The inflammatory cytokine TNF-α was significantly upregulated in GB-
bearing CD73-/- mice compared with the TNF-α level in GB-bearing WT mice (Fig. 
3.1C). A similar trend was also observed in inflammatory cytokine IL-1β, which was 
increased in GB-bearing CD73-/- mice compared with GB-bearing WT mice (Fig. 3.1D). 
Conversely, the anti-inflammatory cytokine IL-10 was significantly downregulated in 
GB-bearing CD73-/- mice compared with GB-bearing WT mice (Fig. 3.1E). This 
suggested that although a similar number of leukocytes infiltrated GB in WT and CD73-
/- mice, leukocytes with different phenotypes were recruited to the tumor site in the 
absence of host CD73. They generated a different cytokine profile in GB-bearing CD73-
/- mice, which had increased inflammatory cytokines, compared with the cytokine 
profile in GB-bearing WT mice. This also suggested that host CD73 promoted an anti-
inflammatory immune response to GB. Because regulatory T (Treg) cells are one of the 
main producers of IL-10 and are often found infiltrating GB, we next quantified the 
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mRNA level of Treg cell transcription factor Foxp3 in the brains of GB-bearing WT and 
CD73-/- mice. We found that unlike GBs in WT mice, which had a significant increase 
in Foxp3 level, the Foxp3 level in GB-bearing CD73-/- mice was similar to sham mice 
(Fig. 3.1F). This indicated that there was a reduction in Treg cell recruitment in GB-
bearing CD73-/- mice and suggested that the reduction of Treg cells contributed to the 
decreased IL-10 level in GB-bearing CD73-/- mice. These findings suggest that host 
CD73 plays a critical role in inhibiting the inflammatory response to GB, promoting 
Treg cell recruitment to GB. 
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Figure 3.1
 104 
Figure 3.1. Host CD73 attenuates the anti-GB inflammatory immune response. A, 
Immunohistochemistry staining of CD45 (brown) on frozen brain sections from GB- or 
sham-implanted WT and CD73 mice, 3 weeks after implantation (n = 3 – 4 per group 
for GB-bearing mice and n = 1 per group for sham). Solid lines indicate GB border. B, 
Quantification of CD45-positive signal from (A) by positive pixel count (n = 3 – 4 per 
group for GB-bearing mice and n = 1 per group for sham). C, D, E, F, Real time-PCR 
quantification of TNF-α (C), IL-1β (D), IL-10 (E), and Foxp3 (F) mRNA levels from 
GB- or sham-implanted WT or CD73-/- mice, 3 weeks after implantation (n = 3 – 5 per 
group for GB-bearing mice and n = 2 per group for sham). Data represent mean ± SEM. 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 (Student’s two-tailed t-test).
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Host CD73 promotes alternatively activated macrophages (M2) polarization in 
GB. 
GB-infiltrating microglia and macrophages are highly abundant compared with 
other GB-infiltrating leukocytes, and they constitute up to 30% of tumor mass (32–34). 
Because CD73 regulates microglia activation and microglia in CD73-/- mice are more 
activated even under basal conditions (35, 36), we wanted to elucidate whether 
microglia and macrophages contributed to the altered cytokine profile seen in GB-
bearing CD73-/- mice. We stained brain sections from GB-bearing WT and CD73-/- mice 
for the microglia and macrophage marker Iba1 and found that there was a significant 
decrease in Iba1 expression in GBs in CD73-/- mice (Fig. 3.2A and B). This indicated 
that there were less GB-infiltrating microglia and macrophages in CD73-/- mice and 
suggested that host CD73 promoted microglia and macrophage infiltration in GB. 
Because tumor-associated microglia and macrophages are anti-inflammatory in GB and 
support GB pathogenesis (37), we stained GB brain sections with Iba1 and alternatively 
activated (M2) macrophage marker CD206 to test whether this was the case in both GB-
bearing WT and CD73-/- mice. We found that GB-infiltrating microglia and 
macrophages in WT mice highly expressed the M2 marker CD206, whereas GB-
infiltrating microglia and macrophages in CD73-/- mice had significantly reduced 
CD206 expression (Fig. 3.2C and D). This suggests that microglia and macrophages in 
GB-bearing CD73-/- mice are classically activated (M1), pro-inflammatory, and tumor 
suppressive. To investigate whether microglia and macrophages in GB-bearing CD73-/- 
were more pro-inflammatory, we measured arginase and iNOS mRNA levels in brain 
tissues. We found that, compared with sham mice, GB-bearing WT mice had a 100-fold 
increase in arginase levels and a decrease in iNOS levels (Fig. 3.2E and F). However, 
the arginase level in GB-bearing CD73-/- mice was similar to that of sham-implanted 
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mice, and iNOS was significantly increased in GB-bearing CD73-/- mice (Fig. 3.2E and 
F). This indicates that host CD73 promotes M2 polarization of microglia and 
macrophages in GB while in the absence of host CD73, GB-infiltrating microglia and 
macrophages are pro-inflammatory and M1 polarized. 
 We further investigated whether this increased pro-inflammatory response to 
GB in CD73-/- mice was because CD73-/- microglia and macrophages were intrinsically 
more pro-inflammatory. We isolated macrophages from WT and CD73-/- mice, 
stimulated them with LPS, and measured pro-inflammatory cytokine IL-1β mRNA 
levels. We found that CD73-/- macrophages had increased IL-1β levels compared to WT 
macrophages (Fig. 3.2G), suggesting that the lack of CD73 expression on macrophages 
made them intrinsically more pro-inflammatory. When we co-cultured mouse MGPP3 
glioma cells with macrophages and treated them with LPS, we found that CD73-/- 
macrophages still responded stronger to the LPS treatment and had increased IL-1β 
levels compared to WT macrophages under the same conditions (Fig. 3.2G). However, 
compared with non-cocultured macrophages, both WT and CD73-/- macrophages co-
cultured with MGPP3 had reduced IL-1β levels (Fig. 3.2G). This indicates that co-
culturing with glioma cells attenuated the immune response of both WT and CD73-/- 
macrophages against LPS. However, CD73-/- macrophages still initiated a stronger 
inflammatory response even in the presence of glioma cells, suggesting that they were 
intrinsically more pro-inflammatory than WT macrophages. This suggests that CD73-/- 
macrophages induced a stronger inflammatory response even in the GB 
microenvironment. 
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Figure 3.2
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Figure 3.2. CD73 on macrophages intrinsically promotes an anti-inflammatory M2 
phenotype in GB immune microenvironment. A, Immunohistochemistry staining of 
Iba1 (brown) on frozen brain sections from GB- or sham-implanted WT and CD73 mice, 
3 weeks after implantation (n = 3 per group for GB-bearing mice and n = 1 per group 
for sham). B, Quantification of Iba1 positive signal from (A) by positive pixel count (n 
= 3 per group for GB-bearing mice and n = 1 per group for sham). C, Immunofluorescent 
staining of Iba1 (green), CD206 (red), and cell nuclei (blue) on frozen brain sections 
from GB- or sham-implanted WT or CD73-/- mice, 3 weeks after implantation (n = 7 – 
9 per group for GB-bearing mice and n = 3 – 4 per group for sham). D, CD206 staining 
was quantified by counting the number of positively stained cell per microscopic field 
from 3 representative microscopic fields per sample (n = 7 – 9 per group for GB-bearing 
mice and n = 3 – 4 per group for sham). E, F, Real time-PCR quantification of arginase-
1 (E) (n = 3 per group for GB-bearing mice and n = 1 for sham) and iNOS (F) (n = 4 – 
5 for GB-bearing mice and n = 1 – 2 for sham) brain mRNA levels from GB- or sham-
implanted WT or CD73-/- mice, 3 weeks after implantation. G, Real time-PCR 
quantification of IL-1β mRNA levels from WT or CD73-/- macrophages co-cultured 
with GL261 cells and treated with LPS or controls (n = 3-4 per group). Data represent 
mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 (Student’s two-tailed t-test).
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Host CD73 inhibits cytotoxic T cell infiltration in GB. 
 Besides microglia and macrophages, we investigated whether cytotoxic T cells 
responded to GB differently in CD73-/- mice compared with WT mice. We hypothesized 
that more cytotoxic CD8+ T cells infiltrated GBs in CD73-/- mice compared to GBs in 
WT mice. Indeed, we observed increased tumor-infiltrating CD8+ T cells in GB-bearing 
CD73-/- mice compared with GB-bearing WT mice (Fig. 3.3A and B). Additionally, 
these tumor-infiltrating CD8+ T cells expressed the T cell activation marker CD44 (Fig. 
3.3A), indicating that they are cytotoxic effector T cells. This suggests that host CD73 
inhibits cytotoxic CD8+ T cell response to GB.
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Figure 3.3 
Figure 3.3. Host CD73 inhibits cytotoxic T cell infiltration in GB. A, 
Immunofluorescent staining of CD44 (green), CD8 (red), and cell nuclei (blue) on 
frozen brain sections from GB- or sham-implanted WT or CD73-/- mice, 3 weeks after 
implantation (n = 4 – 7 per group for GB-bearing mice and n = 3 per group for sham). 
B, CD8 staining was quantified by counting the number of positively stained cells per 
microscopic field from 3 representative microscopic fields per sample (n = 4 – 7 per 
group for GB-bearing mice and n = 3 per group for sham). Data represent mean ± SEM. 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 (Student’s two-tailed t-test).
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CD73 promotes leukocyte entry into the brain parenchyma by permeating the glia 
limitans barrier. 
 The increased pro-inflammatory response in GB-bearing CD73-/- mice 
compared with GB-bearing WT mice led us to hypothesize that Treg cell recruitment to 
the site of GB was inhibited in CD73-/- mice. To test this hypothesis, we first analyzed 
mRNA levels of the the macrophage-derived chemokine CCL22 in the brain tissues of 
GB-bearing mice. CCL22 is mostly produced by M2 microglia and macrophages, and 
it promotes Treg cell recruitment (38). We found a decrease in CCL22 levels in GB-
bearing CD73-/- mice compared with GB-bearing WT mice (Fig. 3.4A). This suggested 
that CD73 promoted CCL22 production in GB-bearing WT mice. We also found a 
decrease in mRNA levels of the Treg cell chemokine receptor CCR4 in GB-bearing 
CD73-/- mice (Fig. 3.4B). Treg cells are recruited to the brain by sensing the 
microglia/macrophage-generated CCL22 concentration gradient through their 
chemokine receptor CCR4. Thus, a reduction in both CCL22 and CCR4 in GB-bearing 
CD73-/- mice suggests that the lack of host CD73 leads to reduced CCL22 secretion, and 
thereby decreases Treg cell recruitment in GB-bearing CD73-/- mice (Fig. 3.1F). 
 To investigate whether CD73 regulated other leukocyte recruitment pathways in 
GB-bearing mice, we next quantified leukocytes’ ability to cross the blood-brain barrier 
(BBB) and the glia limitans layer to enter the brain parenchyma in GB (Fig. 3.4C). We 
stained brain sections from GB-bearing WT and CD73-/- mice and found that in GB-
bearing CD73-/- mice, significantly more CD45+ leukocytes were trapped in the 
perivascular space and were not able to cross the glia limitans barrier (Fig. 3.4D and 
E). Conversely, CD45+ leukocytes in GB-bearing WT mice were able to pass the glia 
limitans layer and enter the brain parenchyma (Fig. 3.4D). This suggests that CD73 
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promotes leukocyte recruitment to the GB brain parenchyma by regulating their ability 
to cross the glia limitans barrier.
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Figure 3.4
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Figure 3.4. CD73 promotes leukocyte entry into the brain parenchyma by opening 
the glia limitans barrier. A, B, Real time-PCR quantification of CCL22 (A) (n = 5 for 
GB-bearing mice and n = 2 for sham) and CCR4 (B) (n = 5 for GB-bearing mice and n 
= 2 for sham) mRNA expression from brains of GB- or sham-implanted WT or CD73-
/- mice, 3 weeks after implantation. C, Drawings demonstrating the blood-brain barrier 
(BBB), the glia limitans layer, and the perivascular space. D, Immunofluorescent 
staining of CD45 (green), laminin (red), and cell nuclei (blue) on frozen brain sections 
from GB- or sham-implanted WT or CD73-/- mice, 3 weeks after implantation (n = 3 – 
4 for GB-bearing mice and n = 2 for sham). E, CD45 staining was quantified by counting 
the number of positively stained cells per microscopic field from 1 representative 
microscopic field per sample (n = 4 – 5 per group for GB-bearing mice and n = 3 per 
group for sham). Data represent mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 
(Student’s two-tailed t-test).
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Discussion 
In this report, we found that the absence of host CD73 resulted in an increased 
inflammatory host immune response to GB, including reduced Treg cell recruitment, 
increased pro-inflammatory cytokines, and decreased anti-inflammatory cytokines. 
Increased cytotoxic T cell infiltration was also observed in GB-bearing CD73-/- mice. 
CD73-/- microglia and macrophages in GB-bearing CD73-/- mice adopted an M1 
phenotype, which was the opposite of what was normally seen in GB immune 
microenvironments. We also demonstrated that CD73-/- macrophages were intrinsically 
more pro-inflammatory, as they mounted a stronger inflammatory response upon LPS 
treatment, and their response remained higher than that of WT macrophages even when 
they were co-cultured with GB cells. This shows that host CD73 promots M2 
polarization in microglia and macrophages (Figure 3.5A and D). 
Tumor-associated microglia and macrophages are critical in the anti-tumor 
immune response. They are two of the main producers of CCL22, which is a major 
chemokine that recruits Treg cells. Studies have shown that Treg cells isolated from GB 
patients have increased CCR4 than those from healthy controls (39). Blocking CCR4 
with antibodies inhibited Treg cell migration (39). Therefore, this suggests that M1 
polarization of microglia and macrophages in GB-bearing CD73-/- mice leads to the 
reduction of Treg cell recruitment because CCL22 is produced mostly by M2 
microglia/macrophages (Figure 3.5B and E). Reduced Treg cells in the GB immune 
microenvironment in CD73-/- mice further increase the pro-inflammatory response to 
GB in CD73-/- mice. 
Although a similar number of GB-infiltrating CD45+ leukocytes were observed 
in WT and CD73-/- mice, more CD45+ leukocytes were trapped in the perivascular space 
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of GB-bearing CD73-/- mice. This indicates that host CD73 promotes passage of 
leukocytes across the glia limitans barrier and entering the brain parenchyma (Figure 
3.5C and F). GB releases factors, including M-CSF, TGFβ, PGE, IL-1, IL-10 and 
FGL2, to attenuate the immune response (40). Therefore, it was interesting to find that 
the immune responses mounted against GB in CD73-/- mice were not attenuated, unlike 
the anti-inflammatory immune responses found in GB-bearing WT mice. It is plausible 
that the glia limitans barrier in the GB-bearing CD73-/- mice partly prevented factors 
secreted by GB to attenuate the leukocytes trapped inside the perivascular space, 
allowing them to maintain their anti-GB, inflammatory properties. 
Although CD73 plays an important role in regulating GB pathogenesis, the host 
immune response also contributes greatly to tumor development. We have shown in this 
report that CD73-/- mice mounted a much stronger inflammatory response against GB 
than WT mice expressing CD73. This suggested that the overall increased inflammation 
in the GB microenvironment in GB-bearing CD73-/- mice contributed to the GB size 
reduction. However, GB still developed in CD73-/- mice and was still aggressive and 
life threatening in the CD73-/- mice. This suggests that removing host CD73 and 
extracellular adenosine is not sufficient to completely inhibit GB growth. However, 
because of CD73’s prominent role in regulating GB pathogenesis and the host anti-GB 
immune response, targeting the CD73/adenosine axis has great potential to improve GB 
treatment and prolong patients’ life span when combined with other treatments. 
 117 
Figure 3.5
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Figure 3.5. Working model describing how CD73 regulates the tumor immune 
microenvironment in GB. A, CD73 on microglia promotes an M2 microglia phenotype 
in the GB microenvironment. B, M2 microglia produce CCL22 and recruit Treg cells to 
the GB site, further attenuating the inflammatory response in the GB microenvironment. 
C, CD73 on leukocytes promotes entry to the brain parenchyma. D, CD73-/- microglia 
are intrinsically more pro-inflammatory and adapt an M1 microglia phenotype in the 
GB microenvironment. E, CD73-/- M1 microglia reduce their production of CCL22 and 
result in limited Treg cell recruitment, allowing the inflammatory response to continue. 
F, CD73-/- leukocytes are trapped in the perivascular space and cannot enter the brain 
parenchyma. The glia limitans layer shields them from factors secreted by GB and 
allows them to maintain their inflammatory state.
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CHAPTER 4 
 
Summary, Conclusions, and Future Directions 
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 Previous studies have shown that CD73 is overexpressed in multiple cancer cell 
lines and patient biopsy samples, including GB (1). Because CD73-generated 
extracellular adenosine is a strong anti-inflammatory molecule that signals through the 
A2A AR on leukocytes to attenuate inflammation, it is used by cancer cells to promote 
tumor immune evasion (2). The ongoing interest in CD73 and adenosine lies in 
determining the role of CD73 and adenosine in specific cancers. This information can 
potentially allow us to target CD73 and/or adenosine signaling to improve cancer 
treatments. It has been shown that CD73 promotes breast cancer angiogenesis (3), 
proliferation, and metastasis (4, 5) and is associated with a worse diagnosis for patients 
with triple negative breast cancer (6). CD73 expression is also associated with reduced 
overall survival among patients and used as a poor prognosis biomarker in gastric cancer, 
colorectal cancer, and gallbladder cancer (7–10). However, it is still unclear how CD73 
and adenosine contribute to GB pathogenesis. 
In this dissertation, we demonstrated that CD73 promoted GB pathogenesis 
through multiple pathways. We found that CD73 was expressed on both the human and 
the mouse GB cell lines. When we implanted mouse GB cells in WT and CD73-/- mice, 
GB-CD73 was increased in CD73-/- mice compared with WT mice. This suggests that 
host CD73 plays a critical role in GB pathogenesis and that GB-CD73 and host CD73 
had overlapping roles in GB pathogenesis. Additionally, we found that GB size and 
invasiveness were both decreased in CD73-/- mice. To test whether host CD73 promoted 
GB invasiveness, we generated the CD73-FLK mouse model by enforcing CD73 
expression on endothelial cells in CD73-/- mice under the control of the Flk-1 promoter. 
This allowed us to determine whether having limited host CD73 in the environment 
initiated GB cells to migrate from their point of implantation to gain access to the host 
CD73, making GB more invasive. Indeed, we found that GB was the most invasive in 
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CD73-FLK mice compared with GBs in CD73-/- and WT mice. Furthermore, GB-
bearing CD73-FLK mice had a significantly reduced survival time compared to GB-
bearing CD73-/- mice. Overall, these findings demonstrate that host CD73 promotes GB 
invasiveness, and that the absence of host CD73 prolongs the survival time in GB-
bearing mice. In future studies, we would like to determine whether inhibiting CD73 
activity using the CD73 inhibitor α,β-methylene ADP (meADP) or blocking CD73 with 
anti-CD73 antibodies prolongs survival in GB-bearing WT mice. If CD73 is promoting 
GB pathogenesis through its enzymatic activity, meADP or anti-CD73 antibody 
treatment will reduce GB growth and invasiveness and prolong GB-bearing mice 
survival. 
To determine how the absence of host CD73 resulted in reduced GB growth, we 
analyzed whether GB angiogenesis was altered in CD73-/- mice. We showed that GB 
vessel density was significantly decreased in CD73-/- mice compared with WT mice, 
with an increase in intravascular proliferation. Furthermore, more glomeruloid vessels 
were found in GB-bearing CD73-/- mice. Because CD73 has been shown to regulate 
tumor angiogenesis through VEGF (11, 12), we first quantified VEFG expression in 
GB-bearing CD73-/- and WT mice. We showed that VEGF expression was upregulated 
in GB-bearing CD73-/- mice compared with GB-bearing WT mice. Because VEGF 
promotes endothelial cell proliferation (13, 14), this increased VEGF likely contributed 
to the increased intravascular proliferation observed in GB-bearing CD73-/- mice. To 
investigate why GB in CD73-/- had decreased vessel density despite the upregulated 
VEGF, we hypothesized that endothelial cells in GB-bearing CD73-/- mice had reduced 
migratory ability and that the mother vessels were not able to divide into smaller vessels, 
resulting in the formation of glomeruloid vessels. Therefore, we quantified the α-
dystroglycan expression in GB-bearing mice. α-dystroglycan is a membrane receptor 
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that tethers endothelial cells to the basement membranes of vessels and limits 
endothelial cell migration (15, 16). We found that α-dystroglycan expression was 
increased in GB vessels in CD73-/- mice compared with those in WT mice. Increased α-
dystroglycan suggests that GB endothelial cells in CD73-/- mice are bound to the 
basement membrane more tightly and resulted in the formation of glomeruloid vessels . 
This then suggests that host CD73 limits GB endothelial cell tethering to the 
extracellular matrix (ECM), which promotes mother vessels to divide and increased GB 
vessel density. In the absence of host CD73, increased VEGF and α-dystroglycan 
expression promote glomeruloid vessel formation. 
Because both angiogenesis and GB invasion requires remodeling of the ECM, 
we next investigated the MMP activity in GB-bearing mice. MMP2 and MMP9 are both 
associated with GB (17, 18), and we found that MMP9 was mostly expressed along the 
tumor edge, while MMP2 mostly surrounded the GB vasculature. We also showed that, 
compared with GB-bearing WT mice, MMP activity in GB-bearing CD73-/- mice was 
decreased overall. Because α-dystroglycan digestion by MMP and remodeling of the 
ECM are essential steps for tumor angiogenesis, this reduction in MMP activity in GB-
bearing CD73-/- mice potentially hindered GB angiogenesis. Furthermore, we also found 
the MMP9 inhibitor TIMP1 increased in GB-bearing CD73-/- mice, with reduced 
expression of TIMP1 in GB-bearing CD73-FLK mice. MMP9 expression was also 
increased along the tumor edge in GB-bearing CD73-FLK mice. This demonstrated a 
positive correlation between MMP9 activity and GB invasiveness. Overall, our findings 
suggest that host CD73 upregulates MMP activity in GB to promote GB angiogenesis 
and invasiveness. A possible future study is to identify whether MMP2 and MMP9 are 
generated by GB cells or by host cells in GB-bearing mice. Because it was not GB-
CD73 but host CD73 that promoted MMP activity in GB-bearing mice, we hypothesize 
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that the host cells in the tumor microenvironment are the main producers of MMPs. A 
future goal will be to implant WT GB in MMP2 knockout and MMP9 knockout mice 
and measure GB angiogenesis, invasiveness, and MMP activity in these mice. If the 
host cells are the main MMP producers in GB-bearing mice, we expect to see reduced 
GB angiogenesis in MMP2-/- mice and decreased GB invasiveness in MMP9-/- mice at 
levels similar to GBs in the CD73-/- mice. If GB cells are the main MMP producers, GB 
angiogenesis and invasiveness should not be affected in MMP2-/- or MMP9-/- mice. 
To elucidate whether CD73 regulates MMPs through adenosine receptor 
signaling, we quantified ARs expression in GB-bearing mice. We found that A2B AR 
expression was highly upregulated in GB compared with other ARs. A2B AR expression 
in the CNS is normally very low under physiological conditions and is only upregulated 
during pathological conditions (19–21). Therefore, the high A2B AR expression we 
observed in GB suggested that it was involved in GB pathogenesis. We next investigated 
whether A2B AR signaling was involved in regulating MMP activity. We found that A2B 
AR signaling in GL261 mouse GB cells increased MMP2 mRNA levels, while 
inhibition of the A2B AR decreased GL261 MMP activity. This indicated that the 
increased GB-CD73 in GB-bearing CD73-/- mice induced MMP2 expression through 
A2B AR signaling. However, in the absence of host CD73, the overall MMP activity was 
decreased. This suggested that host CD73 was the main regulator of MMP activity. Host 
CD73 upregulated MMP9 and inhibited TIMP1 expression to promote GB invasiveness. 
In the absence of host CD73, GB-CD73 increased MMP2 expression but was not able 
to increase the overall MMP activity in GB. This indicated that increased GB-CD73 in 
GB-bearing CD73-/- mice could not fully compensate for the lack of host CD73. 
Because we previously found that AR signaling regulated MDR transporters on 
the BBB, we next investigated whether A2B AR signaling regulated MDR transporters 
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in GB. We showed that both P-gp and MRP1 were upregulated in GB-bearing mice, and 
their expression were significantly higher in GB-bearing CD73-/- mice than in GB-
bearing WT mice. We also demonstrated that inhibiting A2B AR signaling 
downregulated P-gp and MRP1 expression on GB cells, increased P-gp substrate Rho-
123 uptake, and increased TMZ-induced cell death. We therefore concluded that A2B 
AR signaling promoted GB chemoresistance by upregulating MDR transporters on GB. 
In a future experiment, we would like to knockout the A2B AR in GL261-luciferase GB 
cells and test if A2B AR-/- GB is be more sensitive to TMZ treatment. We will implant 
A2B AR-/- GB and WT GB into WT mice and allow the tumor to develop for 2 weeks 
before TMZ treatment. This will allow us to monitor GB size in real-time through the 
luciferase activity on GB and quantify TMZ efficacy in A2B AR-/- GB and WT GB-
bearing mice. Because the A2B AR regulates MDR transporters on GB, we expect to see 
increased TMZ sensitivity and prolonged survival in TMZ-treated mice with A2B AR-/- 
GB compared with WT GB. 
Because adenosine signaling through the A2A AR has been shown to attenuate 
the immune response in cancer (2), we next investigated whether the anti-tumor immune 
response was stronger in the GB-bearing CD73-/- mice. We found a similar number of 
CD45+ tumor-infiltrating leukocytes in GB-bearing WT and CD73-/- mice. However, 
the cytokine profile in GB-bearing CD73-/- mice was very different from GB-bearing 
WT mice. We found an increase in pro-inflammatory cytokines TNF-α and IL-1β in 
GB-bearing CD73-/- mice compared with GB-bearing WT mice. Conversely, the anti-
inflammatory cytokine IL-10 was significantly higher in GB-bearing WT mice 
compared with GB-bearing CD73-/- mice. Additionally, we found that, unlike GB-
bearing mice, microglia and macrophages in GB-bearing CD73-/- mice had a pro-
inflammatory phenotype. They had reduced CD206 and arginase-1 expression and 
  
 129 
increased iNOS expression. We demonstrated that CD73-/- macrophages were 
intrinsically more pro-inflammatory compared with WT macrophages. Furthermore, we 
showed that GB-bearing CD73-/- mice had more activated CD8+ T cell infiltration and 
reduced Treg cell infiltration compared to GB-bearing WT mice. Overall, we 
demonstrated that host CD73 attenuated the anti-GB immune response. To elucidate 
whether this increased inflammatory response in GB-bearing CD73-/- mice is a direct 
result of the lack of CD73 on GB-infiltrating leukocytes, we propose implanting GB in 
bone marrow chimeric mice generated from CD73-/- and WT mice as a future study. We 
will transfer bone marrow from WT mice into irradiated CD73-/- and WT mice, and 
bone marrow from CD73-/- mice into irradiated WT mice and CD73-/- mice. The 
chimeric mice will be allowed to reconstitute for 45 days before GB implantation. Three 
weeks after GB implantation, we will analyze the cytokine profiles, the GB-infiltrating 
immune cell types, and their phenotype in the GB-bearing chimeric mice. We expect 
chimeric mice with CD73-/- bone marrow donors to have a stronger inflammatory 
response to GB, and we also expect chimeric mice with WT bone marrow donors to 
have an anti-inflammatory immune response. This is because Treg cells highly infiltrate 
the tumor and elicit some of their immune-attenuating functions through their surface 
CD73 expression (22). In the absence of CD73 expression on Treg cells, their immune-
attenuating functions may be reduced. Additionally, because we found that CD73-/- 
macrophages were intrinsically more proinflammatory, chimeric mice with CD73-/- 
bone marrow donors may elicit a stronger inflammatory response. 
The dramatic difference in the immune profiles between GB-bearing WT mice 
and GB-bearing CD73-/- mice led us to investigate whether Treg recruitment in GB-
bearing CD73-/- mice was inhibited. We found that the macrophage-secreted Treg cell 
recruitment cytokine CCL22 and its receptor CCR4 were decreased in GB-bearing 
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CD73-/- mice compared with GB-bearing WT mice. In addition, leukocytes were trapped 
in the perivascular space and blocked by the glia limitans layer in GB-bearing CD73-/- 
mice. Therefore, we proposed that the more pro-inflammatory CD73-/- macrophages and 
microglia had reduced CCL22 production. This led to decreased Treg cell recruitment 
in GB-bearing CD73-/- mice and an overall increase in the anti-tumor inflammatory 
response. Additionally, an increase in leukocytes trapped in the perivascular space 
indicated that CD73 was required for leukocyte entry into the brain parenchyma. In 
future studies, we will identify the leukocytes trapped in the perivascular space in the 
GB-bearing CD73-/- mice and compare them with leukocytes that exited the glia limitans 
layer. Because GB-bearing CD73-/- mice elicited a stronger anti-tumor immune response, 
we hypothesize that leukocytes trapped in the perivascular space may be physically 
blocked from GB-secreted factors and thus able to better maintain their anti-tumor 
properties. We will separate leukocytes trapped in the perivascular space from 
leukocytes in the brain parenchyma through laser microdissection and identify their 
phenotype through flow cytometry. We expect to see more pro-inflammatory leukocytes, 
including M1 macrophages and cytotoxic T cells, inside the perivascular space 
compared with leukocytes in the brain parenchyma. 
In sum, we demonstrated that CD73 and adenosine signaling are key modulators 
of GB pathogenesis and the anti-GB immune response. We showed that host CD73 
promoted GB angiogenesis and invasiveness through the regulation of MMP activity, 
which critically impacted GB growth and GB-bearing mice survival time. We also 
showed that A2B AR signaling promoted GB chemoresistance by upregulating the MDR 
transporters P-gp and MRP1 on GB cells. Inhibition of A2B AR signaling effectively 
increased TMZ-induced GB cell death in vitro. Additionally, we demonstrated that host 
CD73 modulated the anti-GB immune response by attenuating inflammation, increasing 
  
 131 
GB-infiltrating Treg cells, and polarizing microglia and macrophages into an anti-
inflammatory phenotype. Therefore, when targeting CD73 and adenosine as a potential 
treatment for GB patients, it has to be taken into account that CD73 and adenosine 
signaling have a multi-faceted influence on GB pathogenesis and host anti-GB immune 
responses. Overall, our findings demonstrate that inhibition or blockade of CD73 and/or 
extracellular adenosine signaling pathway present great potentials for future GB 
therapeutic interventions.
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APPENDIX 
SUMMARY OF ADDITIONAL PUBLICATIONS: 
Non-alcoholic fatty liver disease induces signs of Alzheimer’s disease (AD) in 
wildtype mice and accelerates pathological signs of AD in an AD model 
and 
Toxoplasma gondii alters NMDAR signaling and induces signs of Alzheimer’s disease 
in wild-type, C57BL/6 mice
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Alzheimer’s disease (AD) is an irreversible and progressive neurodegenerative 
disease that leads to declined cognitive function, loss of memory, and eventually the 
inability to carry out daily tasks (1). The major neuropathological hallmarks of AD 
include senile amyloid plaques composed of β-amyloid (Aβ) protein and intracellular 
neurofibrillary tangles comprised of hyperphosphorylated tau protein aggregates (1). 
Current treatments for AD only reduce the symptoms and no cure is available. Common 
risk factors associated with AD include advanced age, environmental stressors, and 
genetic factors (2, 3). Additionally, consumption of a high-fat diet, obesity, and 
cholesterol-uptake receptors involved in cholesterol metabolism, such as low-density 
lipoprotein receptor-related protein 1 (LRP1) and apoliprotein-E (ApoE), are important 
risk factors contributing to the prevalence of AD (4–7). We therefore investigated non-
alcoholic fatty liver disease (NAFLD)-induced liver inflammation in the pathogenesis 
of AD in C57/BL6 wild-type (WT) and AD transgenic mouse model (APP-Tg) mice. 
We found that, during the acute phase of NAFLD, both WT and APP-Tg mice 
developed significant liver inflammation and pathology that coincided with increased 
numbers of activated microglial cells in the brain, increased inflammatory cytokine 
profile, and increased expression of toll-like receptors (8). Chronic NAFLD induced 
advanced pathological signs of AD in both WT and APP-Tg mice, and also induced 
neuronal apoptosis (8). We observed decreased brain expression of LRP-1, which is 
involved in β-amyloid clearance, in both WT and APP-Tg mice after 1 year of being on 
the HFD (8). Removal of mice from HFD during acute NAFLD reversed liver pathology, 
decreased signs of activated microglial cells and neuro-inflammation, and decreased β-
amyloid plaque load (8). Our findings indicate that chronic inflammation outside of the 
CNS is sufficient to induce neurodegeneration and advanced pathological signs of AD 
in WT mice. 
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In addition to chronic inflammation induced by NAFLD, Toxoplasma gondii (T. 
gondii), which directly infects the CNS, has also been implicated as a contributor to 
Parkinson’s disease, schizophrenia, obsessive compulsive disorder, and Tourette 
syndrome (9). However, little is known about the impact of T. gondii infection on 
neuronal cells. We infected male and female WT mice with 10 T. gondii ME49 cysts 
and assessed whether infection led to behavioral and anatomical effects. We show that 
T. gondii infection induced two major hallmarks of AD in the brains of both male and 
female WT mice: Aβ immunoreactivity and hyperphosphorylated Tau (10). Infected 
male and female mice showed significant neuronal death, loss of N-methyl-D-aspartate 
receptor (NMDAR) expression, and loss of olfactory sensory neurons (10). T. gondii 
infection also caused anxiety-like behavior, altered recognition of social novelty, altered 
spatial memory, and reduced olfactory sensitivity (10). This last finding was exclusive 
to male mice, as infected females showed intact olfactory sensitivity (10). These 
findings indicate that T gondii infection induces advanced pathological signs of AD in 
WT mice. Together, these two studies demonstrated that inflammation both in and 
outside of the CNS have significant neurodegenerative effects in the CNS that lead to 
advanced pathological signs of AD. 
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